J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102 Version 2.0 February 5, 2020 
Protocol Version Date:  February 5, 2020 
Local Protocol #: NA_00085870, J1369  
Title:  A phase I study of SGI-110 combined with  irinotecan followed by a randomized 
phase II study of SGI-110 combined with ir inotecan versus regorafenib or TAS-102 
(lonsurf)
 in previously treated meta static colorectal  cancer patients 
Principal Investigator:   Nilofer Azad, MD 
Bunting-Blaustein Cancer  Research Building I 
1650 Orleans Street, Room 4M10  
Baltimore, MD 21231 (p)410-614-9169; (f )410-614-9006,
Email:  nazad2@jhmi.edu
Coordinating Center: Sidney Kim
mel Comprehensive Can cer Center at Johns Hopkins 
USC Investigator:  Anthony el-Khoueiry, MD (site PI) 
University of Southern California 
V U M C  I n v e s t i g a t o r :  Henk Verheul, MD PhD (site PI) 
VU University Medical Center, Netherlands 
MSKCC Investigator: Andrea Cercek, MD (site PI) 
Memorial Sloan Kettering Cancer Center 
Statistician:  Marianna L. Zahurak 
Division of Oncology Biosta tistics and Bioinformatics 
The Sidney Kimmel Comprehe nsive Cancer Center 
550 N. Broadway, Suite 1103 Baltimore, MD 21287 Office: 410-955-4219 Fax: 410-955-0859 Email: zahurma@jhmi.edu  
SKCCC 
Study Coordinator:  Tearra Miles 
 Research Coordinator  
The Sidney Kimmel Comprehens ive Cancer Center at 
Johns Hopkins 
 201 North Broadway  8th floor Space   8120-43 
Baltimore, MD 21205-2009 Phone: 410-502-5328 Fax: 410-502-0834 Email: tlawre18@jhmi.edu ClinicalTrials.gov ID: [STUDY_ID_REMOVED]
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. Do not disclose or use except as  authorized.  SKCCC Research Nurse:      Ellen Lilly-Foreman 
Johns Hopkins Kimmel Cancer Center  Research Nurse-GI Oncology 201 N. Broadway,  Baltimore, MD 21205 
Phone: 443-287-4961 
Fax: 410-502-0834 Email: lillyel@jhmi.edu 
 
   
Sponsor:            N i l o f e r  A z a d ,  M D  
I N D :             IND 118733  
Protocol Type/Version/Version Date:  Revised/ Version 1.8 / June 10, 2016 
 
SCHEMA 
 
Stage I 
 
   
 
 
 
 
      
 
 
Stage II 
 
                R 
A 
                                           N 
 mCRC                               D 
pts           O 
                                         M 
I 
Z 
E 
  Treatment 
  ARM A: SGI-110 45mg/m2 SC D1-5 
+ Irinotecan 125mg/m2 D8,15 with 
mandatory growth factor support on cycle 1  
  2:1 
 ARM B: Regorafenib 160 mg qd days 1-21 
or TAS-102 35mg/m2 BID on 
days 1-5 and 8-12 on 28 day cycle 
 
 
Start at 
dose level 1 Treat cohort (3 participants) 
Number 
of DLTs De-
escalate 
one dose 
level 
Recruit 3 more 
participants 
Further 
DLTs? StopEscalate dose or, if 
DL2, stop at this MTD 
Yes No 1 or 0 on DL2 2 or 3 
0
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. Do not disclose or use except as  authorized.  1. OBJECTIVES .................................................... ............................................................... ................................. 1  
1.1	Study De sign .................................................................................................................. .................................. 1 	
1.2	Primary Obje ctives ............................................................................................................ .............................. 1 	
1.3	Secondary Ob jectives .......................................................................................................... ............................ 1 	
2. BACKGROUND .................................................... ............................................................... ............................. 1  
2.1	SGI-110 ....................................................................................................................... .................................... 1 	
2.2	Irinot ecan .................................................................................................................... .................................... 6 	
2.3 Regora fenib ............................................................................................................... .......................................... 7 	
2.4	TAS-102 (Lonsurf) ............................................................................................................. .............................. 8 	
2.5	Study disease: colo rectal c ancer .............................................................................................. ....................... 9 	
2.6	Rationale ..................................................................................................................... .................................. 10 	
3. PARTICIPANT SELECTI ON ......................................... ............................................................... ................ 12  
3.1	Eligibility Cr iteria .......................................................................................................... ............................... 12 	
3.2	Exclusion Criteria ............................................................................................................ .......................... 13 	
3.3	Inclusion of Women, Minorities and Ot her Underrepresented Populations ................................................. 15 	
4 REGISTRATION PROCEDURES ....................................... ............................................................... .......... 15  
4.1	General Guidelines ............................................................................................................ ........................... 15 	
4.2	Registration Process .......................................................................................................... ........................... 15 	
4.3  Patient assignment and randomiza tion procedure for second coho rt ........................................................ 16  
5 TREATMENT PLAN ................................................ ............................................................... ....................... 16  
5.1	Overall Stud y Desi gn .......................................................................................................... .......................... 16 	
5.2	Screening and pre-treatment criteria .......................................................................................... ............... 19 	
5.3	Agent Administration .......................................................................................................... ......................... 21 	
5.4	Definition of Dose-Limiting Toxicity .......................................................................................... ................ 22 	
5.5	General Concomitant Medication an d Supportive Care Guidelines ............................................................. 23 	
5.6	Duration of Therapy ........................................................................................................... ............................ 23 	
5.7	Duration of Follow Up ......................................................................................................... ......................... 24 	
5.8	Cross Over in  Phase II ........................................................................................................ .......................... 24 	
5.9	Criteria for Removal fr om Study Treatment ..................................................................................... ............. 24 	
6 EXPECTED TOXICITIES AND DOSING DELAYS/DOSE MODIFICATIONS ...... .............................. 25  
6.1	Anticipated Toxic ities ........................................................................................................ ............................ 25 	
6.2	Toxicity M anagement ........................................................................................................... ......................... 27 	
6.3	Dose Modifica tions/Delays ..................................................................................................... ...................... 27 	
7 DRUG FORMULATION AND ADMINISTRATION ........................... ...................................................... 30  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. Do not disclose or use except as  authorized.  7.1	SGI-110 ....................................................................................................................... .................................. 30 	
7.2	Irinotecan .................................................................................................................... .................................. 32 	
7.3	Regorafe nib ................................................................................................................... ................................ 33 	
7.4	TAS-102 (Lonsurf) ............................................................................................................. ............................ 34 	
8 CORRELATIVE/SPECI AL STUDIES ................................... ............................................................... ........ 36  
8.1	Archival tissue ............................................................................................................... ................................ 37 	
8.2	Pharmacokineti c Studies ....................................................................................................... ........................ 37 	
8.3	Pharmacodynamic Studies ....................................................................................................... ..................... 39 	
9 STUDY CALENDARS ............................................... ............................................................... ...................... 46  
10 MEASUREMENT OF EFFECT.......................................... ............................................................... ............ 53  
10.1	Antitumor Effect– Solid Tu mors ................................................................................................ .................... 53 	
10.2	Other Response Parameters ..................................................................................................... ..................... 59 	
11 ADVERSE EVENT REPORTING REQUIREMENTS .......................... ..................................................... 60  
11.1	Definitions ................................................................................................................... .................................. 60 	
11.2	Procedures for AE and SAE Recording and Repor ting ............................................................................. .... 62	
11.3	Reporting Requ irements ........................................................................................................ ........................ 62 	
11.4	Reporting to the Study Sponsor ................................................................................................ ..................... 62 	
11.5	Reporting to the Institutional Review  Board (IRB) ............................................................................. .......... 63	
11.6	Reporting to the Food and Drug Administration (FDA) ........................................................................... .... 64	
11.7	Reporting to Hospital  Risk Management.......................................................................................... ............. 65 	
11.8	Monitoring of Adverse Events and Period of Observa tion ........................................................................ .... 65	
12 DATA AND SAFETY MONITORING .................................... ............................................................... ....... 65  
Adverse event lists, guidelines, a nd instructions for AE report ing can be found in Section 11.0 (Adverse Events: 
List and Reporting Requirements). ............................. ............................................................... ............................... 65  
13 REGULATORY CONSIDERATIONS ..................................... ............................................................... ...... 66  
13.1	Protocol Review and Amendm ents ................................................................................................ ................ 66 	
13.2	Informed Consent .............................................................................................................. ............................ 66 	
13.3	Ethics and Good Clin ical Practi ce (GCP) ....................................................................................... ............. 66 	
13.4	Study Docume ntation ........................................................................................................... ......................... 67 	
13.5	Records Re tention ............................................................................................................. ............................ 67 	
13.6	Data Coll ectio n ............................................................................................................... .............................. 67 	
13.7	Multi-center Gu idelines ....................................................................................................... .......................... 68 	
14 STATISTICAL CONSIDERATIONS .................................... ............................................................... ......... 69  
14.1	Study Design/E ndpoints ........................................................................................................ ........................ 69 	
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. Do not disclose or use except as  authorized.  Stratification Factors ........................................................................................................ ...................................... 75 	
14.2	Reporting and Exclusions ...................................................................................................... ........................ 75 	
15 REFERENCES .................................................... ............................................................... .............................. 76  
 
Appendix A: Performan ce Status Criteria ....................... ............................................................... ........................ 80  
APPENDIX B:   P ATIENT D IARY ................................... ............................................................... ....................... 81  
APPENDIX C:   P ATIENT D IARY ................................... ............................................................... ....................... 82  
APPENDIX D: FACT-C (Version 4) ................................ ............................................................... ........................ 82  
  
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020 
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
 
1 1. OBJECTIVES 
1.1 Study Design 
 
This is a phase I/randomized pha se II study of the combination of SGI-110 and irinotecan in 
previously treated metastatic c olorectal cancer patients. This study will be conducted in two 
components.  First, patients will be enrolled in a phase I stud y of SGI-110 combined with 
irinotecan in a standard 3+3 design. After the maximum tolerate d dose (MTD) is determined, 
patients will subsequently be e nrolled in a 2:1 randomized phas e II study of SGI-110 and 
irinotecan versus the standar d of care regorafenib or TAS-102 ( lonsurf). 
 
1.2 Primary Objectives 
 
Phase I Component: Stage I 
--To assess safety and tolerabil ity of combination SGI-110 + ir inotecan in colon cancer patients 
--To determine the phase II dose of the combination of SGI-110 + irinotecan 
 Phase II Component: Stage II 
--To improve median progression-fr ee survival from that reporte d with regorafenib and TAS-102 
to 4 months for SGI-110+irinoteca n in previously treated metast atic colon cancer patients who 
have progressed on irinotecan. 
 
1.3 Secondary Objectives 
 
Phase I Component: Stage I 
--To assess changes in global me thylation and expression at the  tumor level with SGI-110 and 
irinotecan treatment 
--To assess for pharmacokinetic interactions of SGI-110 and iri notecan 
--To assess for correlation betw een disease response and drug e xposure 
 Phase II Component: Stage II 
--To evaluate response rate as determined by RECIST criteria 1. 1  
--To evaluate concurrent SGI-110+ irinotecan treatment versus re gorafenib or TAS-102 alone  
--To improve median overall survi val from historical rate of 6. 4 months 
--To assess for potentia l predictive biomar kers of response and  survival using baseline tissue 
 
2. BACKGROUND 
 
2.1 SGI-110 
 
2.1.1  SGI-110 Background 
 
For further information on SGI-110 please refer to the most up to date version of the 
Investigator’s Brochure (IB).1 
 SGI-110 is a DNA methyltransferas e inhibitor (a demethylating a gent). The active metabolite of 
SGI-110 (2’-deoxy-5-azacytidylyl -(3’→5’)-2’-deoxyguanosine sodi um salt), a dinucleotide, is 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
2 decitabine. SGI-110 is resistan t to modification by cytidine de aminase, a common pathway of 
decitabine metabolism and deactivation.2 The molecular weight of SGI-110 and decitabine are 
580 Da and 228 Da, respectively. The refore, the molar equivalen t dose of 1 mg of decitabine is 
approximately 2.5 mg of SGI-110. SG I-110’s activity was demonst rated with the same 
preclinical pharmacodynamic assays used to demonstrate decitabi ne’s efficacy e.g., re-
expression of p15, p16, and MLH1 and i nduction of fetal hemoglo bin, in vivo . In 
xenograft studies, SGI-110 demons trates promising preclinical a ctivity in both hematologic and 
solid tumors. 
 
In vitro evidence suggests that SGI-110 ha s a longer half-life than deci tabine in the presence of 
cytidine deaminase. These promising observations suggest that S GI-110 has improved 
pharmaceutical properties and biological activities that expand  on decitabine’s current clinical 
utility. SGI-110 has shown to be bett er tolerated in mice than decitabine and is as effective in 
vivo in inducing p16 expression, reduci ng DNA methylation at the p16  promotor region, and 
retarding EJ6 human bladder cancer tumor growth in athymic mice .3 
 
SGI-110 has been developed for subc utaneous administration. SGI -110 is pharmacologically 
active both in vitro and in vivo in a variety of tumor cells and  murine xenograft models when 
administered subcutaneously. Tre atment is well tolerated via th e subcutaneous route in murine 
xenografts. When administered s ubcutaneously to non-human prima tes, SGI-110 releases 
decitabine slowly compared to oth er species, possibly prolongin g the effect over longer periods. 
SGI-110 has been developed as a  non-aqueous formulation to ensu re formulation stability. 
 
2.1.2 Nonclinical pharmacokinetics 
 
The overall pharmacokinetic chara cteristics of S GI-110 are summ arized as follows. The relative 
bioavailability of SGI-110 dosed s ubcutaneously to the rat is c lose to 100%. Circulating SGI-110 
levels were very low in the m ouse, rat and rabbit. However, hig her levels were observed in the 
monkey post subcutaneous dosing. Rap id decline in systemic expo sure of SGI-110 with 
elimination plasma half-life (T1/2) in the range of 0.4-1 hours  in rat and monkey was observed. 
High levels of decitabine were  observed after a subcutaneous do se of SGI-110 in the mouse, rat, 
and rabbit (maximum in rat, 54 μg/mL). Levels in the monkey (ma ximum 463 ng/mL) were 
substantially lower. R apid decline in systemic exposure of deci tabine with elimination plasma 
T1/2 of 3.7 hour in rats and 1 hour i n monkey was observed. 
 In monkey, pharmacokinetic param eters were similar on Day 1 and  Day 15 of a study in which 
they were dosed once weekly for  three consecutive weeks suggest ing no significant 
accumulation of the parent or the active metabolite, decitabine . 
 The metabolic characteristics of  SGI-110 are summarized as foll ows. SGI-110 was  more stable 
in human, dog and mouse and was less stable in rat and rabbit p lasma. Incubation of SGI-110 
with liver microsomes from m ouse, rat, rabbit, dog and human sh owed little apparent 
metabolism of the compound. Inc ubation of SGI-110 with human he patocytes also showed little 
apparent metabolism of the c ompound, based on disappearance of the parent. SGI-110 does not 
significantly bind to human plasma proteins; in vitro unbound fraction was estimated to be 91%. 
SGI-110 has poor in vitro bidirectional permeability whic h correlates well  with its poor oral 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
3 absorption in vivo . SGI-110 shows no appreciable i nduction of CYP1A1/2, CYP2C9 an d 
CYP3A4 in human hepatocytes. S GI-110 does not have any CYP450 i nhibitory effect on 
CYP1A2, CYP2C9, CYP2C 19, CYP2D6 and CYP3A4. 
 
  2.1.3 Nonclinical safety of SGI-110 
 SGI-110 toxicity findings in rat  and rabbit studies are similar  to the non-clinical  study findings of 
decitabine in New Drug Appli cation (NDA) supporting Good Labora tory Practices (GLP) 
toxicology studies. Myelosuppres sion, decreases in thymus weigh t, and testicular atrophy, the 
main study findings of the SGI- 110 studies, were also observed as the main study findings in 
repeat dose toxicity studies wit h decitabine in mice, rats, rab bits, and dogs. As with SGI-110, 
myelosuppression and thymus toxic ities after decitabine adminis tration were reversible during 
recovery periods while testicul ar atrophy persisted. Myelosuppr ession, particularly neutropenia, 
has been reported as a dose-limiting toxicity for decitabine in  human clinical studies. Signs of 
testicular toxicity has not b een observed in any of the publish ed clinical studies of decitabine to 
date.
4 
 No studies have been performed t o evaluate the genotoxic, mutag enic, carcinogenic or 
reproductive and developmental t oxicity of SGI-110. Decitabine may have genotoxic potential; 
decitabine is mutagenic and in pr eclinical studies in mice and rats, decitabine was teratogenic, 
fetotoxic, and embryotoxic.
4 
 
  2.1.4 SGI-110 Clinical Data 
 
SGI-110 is being studied in a fir st-in-human, si ngle-agent stud y (SGI-110-01).5 This study is 
a Phase 1/2, dose escalation, multicenter study of two subcutan eous regimens of SGI-110 in 
subjects with intermediate or hi gh-risk myelodysplastic syndrom es (MDS) or acute myeloid 
leukemia (AML). This study has tw o parts, a Dose Escalation Seg ment and a Dose Expansion 
Segment. The study seeks to evaluate the biological activity, p reliminary safety, and efficacy of 
SGI-110 with two dosing schedules i n intermediate to high risk MDS or relapsed o r refractory 
AML subjects, while the Dose Expa nsion Segment further evaluate s safety and efficacy at the 
recommended dose. The study is based on a 3 + 3 design within e ach regimen. Eligible subjects 
are being randomized to receiv e 1 of 2 dosing regimens of SGI-1 10 with the following starting 
doses: Regimen 1: 3 mg/m2/day subcutaneously on Days 1-5 of a 2 8-day course, Regimen 2: 
6 mg/m2 subcutaneously Weekly x 3 on Days 1, 8, 15 of a 28-day course. As of 23 April 2012, 
the study has enrolled 78 subjec ts into 7 dose cohorts in the D ose Escalation Segment, as shown 
below (Table 1). The minimum dose achieving maximal biological activity or bio logically 
effective dose (BED) for the da ily regimen has been reached at 60 mg/m2 daily on Days 1-5. 
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
4  
 
2.1.5 Human pharmacokinetics 
 
The PK of SGI-110 and decitabine are being evaluated in Study S GI-110-01. Decitabine forms 
from SGI-110 as it undergoes cleavage by phosphodiesterase (PDE ) enzymes. SGI-110 after SC 
injection undergoes efficient c onversion to decitabine and deli vers decitabine exposures as 
measured by AUC that are equivale nt or higher than those achiev ed by IV decitabine infusion at 
20 mg/m2, while maintaining significantly lower decitabine Cmax . It is hypothesized that lower 
Cmax may be associated with less toxicity.  Due to slower release of decitabine from SGI-110, the effective  half-life of decitabine after SC 
SGI-110 is prolonged and the observed decitabine exposure windo w is longer (8+ hrs) compared 
to IV (3-4 hrs). At Cohort 6, doses of 90 mg/m2 for the daily r egimen and 125 mg/m2 for 
weekly, the observed decitabine AUCs were approximately 1.41 an d 1.77 fold higher than with 
IV decitabine at the approved dos e of 20 mg/m2 IV, whereas Cmax  levels were only at 0.35 and 
0.44-fold for the daily and weekly regimens, respectively. It i s hypothesized that longer exposure 
to decitabine may allow more drug to be incorporated into the D NA thus resulting in better 
hypomethylation and better biolog ical activity. Clinical drug-d rug interaction studies have not 
been conducted with SGI-110. In vitro , SGI-110 does not inhibit the activity nor induce levels of 
major human CYP enzymes, hence, t he likelihood of CYP-mediated drug-drug interactions with 
SGI-110 is remote.
5 
   
2.1.6 Clinical efficacy and bi ological activity of SGI-110 
 
Based on PD assessment of global hypomethylation from the first  7 cohorts in Study SGI-110- 
01, the LINE-1 demethylation data show dose dependent hypomethy lation induction in the daily 
schedule reaching a plateau at Cohort 5 (60 mg/m2 SC dailyx5). The hypomethylation of the 
weekly schedule was inferior to the daily schedule and plateaue d early (Figure 1). The 
Biologically Effective Dose or BE D was therefore established as  60 mg/m2 dailyx5. 
 
 
     

J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
5 Figure 1: LINE demethylation 
 
There have been 5 documented major responses (2 CRs and 2 CRi, 1 CRp) all in heavily-
pretreated refractory AML subj ects regardless of  prior hypomet hylating agents (HMA) 
treatment : 1 CR and CRp with weekly (60 mg/m2 and 125mg/m2, re spectively) 
and 2 CRi and 1 CR with daily (36/60 mg/m2 and 60 mg/m2 respect ively). The major responses 
were observed in 5/19 refractor y AML patients when adequate hyp omethylation (>10%) was 
achieved. Five MDS patients who al l received prior treatment wi th HMAs had hematological 
improvements or marrow CR.   As of 27 March 2012, there were 54 subjects who have informatio n in the clinical database in the 
Phase 1/2 study with single-agen t SGI-110. This data cutoff dat e includes all subjects in both 
cohorts up to Cohort 5.  Of the 54 subjects in the clinical  database, 46 (85%) have repo rted at least 1 adverse event (AE). 
There were 26 (48%) subjects with an AE considered related by t he Investigator. The most 
common related AEs, occurring in  at least 3 subjects (6%) in de creasing incidence were injection 
site pain (n=12, 22%);  fatigue (n=6, 11%); nausea (n=5, 9%); an d thrombocytopenia, anaemia 
and diarrhea (n=3, 6%). All of t hese were Grade 1 or 2 AEs with  the exception of 1 subject (1 in 
60 mg/m2 dailyx5) with Grade 4 thrombocytopenia and 2 subjects (1 in 3 mg/m2 dailyx5 and 1 
in 60 mg/m2 dailyx5) with Grade 3 anaemia.  As of 31 May 2012, there were 156 serious adverse events (SAEs)  in 66 subjects in the safety 
database regardless of relations hip to the study drug. The most  common SAEs (≥5%) were 
febrile neutropenia (n=24, 36%) , pneumonia (n=17, 26%), disease  progression (n=7, 11%), 
sepsis (n=6, 8%), pyrexia (n=5, 9%), bacteraemia and skin infec tion (n=4, 6% each). Most 
events were considered not related to study drug as they were e xpected from disease progression 
of the study population (MDS and AM L). Twelve (12) subjects had  SAEs considered by the 
investigator as related to the use of SGI-110: 3 subjects with febrile neutropenia , 2 subjects with 
thrombocytopenia, and 1 subject each with pseudomonal sepsis, a trial fibrillation, chest pain, 
pleural effusion, bacteraemia, sepsis and dysphagia.  

J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
6 As of May 2012, there have been thr ee expedited safety reports submitted to regulatory 
authorities by the Sponsor concer ning suspected adverse reactio ns related to SGI-110: one event 
of pleural effusion for which no ot her cause was established an d did not return upon cessation of 
therapy (at 36 mg/m2 in the week lyx3 regimen) and 2 events of f ebrile neutropenia (both at 
125 mg/m2 dailyx5), one of which w as associated with sepsis tha t resulted in the subject’s death. 
Both febrile neutropenia cases w ere the only 2 cases that were considered as Dose Limiting 
Toxicities (DLTs) and they both oc curred in patients with MDS i n Cohort 7 (125 mg/m2 
dailyx5).The maximum administered dose (MAD) for the dailyx5 re gimen is 125 mg/m2 and the 
MTD is considered to be 125 mg/m 2 dailyx5 for AML patients and 90 mg/m2 dailyx5 for MDS 
based on 2 cases of febrile neutrope nia that were considered as  Dose Limiting Toxicities (DLTs) 
that occurred in patients w ith MDS in Cohort 7 (125 mg/m2 dailyx5).The MTD for the weekly 
regimen was not established a s no DLTs were observed up to the 
highest dose tested of 125 mg/m2 w eeklyx3 regimen. The risks of  SGI-110 in humans are 
described further in Section 6, Expe cted Toxicities. For more d etailed information, please refer 
to the IB for SGI-110. The two m ain drug-relate d adverse reacti ons of SGI-110 are 
myelosuppression (neutropenia, feb rile neutropenia, thrombocyto penia, and anemia) and its 
consequences (such as infec tion, fever, and sepsis), and inject ion-site events such as pain, 
irritation, and inflammation. At the SGI-110 proposed in this s tudy (30-60 mg/m2 daily on Days 
1-5), there have been no reports  of drug-related myelosupressio n in MDS and AML subjects in 
study SGI-110-01. The recommende d starting dose of 45 mg/m2 dai ly on Days 1-5 is 50% of the 
MTD for single-agent treatment with SGI-110 and about one-third  of the MAD based on first-in-
human study SGI-110-01.  Pain and burning at the injection s ite has been reported that a re related to dose and volume of 
injection. Other than these even ts described above, SGI-110 has  been well tolerated up to 
90 mg/m2 dailyx5 and 125 mg/m2 weekly x3. 
 In summary, SGI-110 single agent treatment for MDS and AML pati ents was well tolerated up to 
125 mg/m2 weeklyx3 and 90 mg/m2 dailyx5 given every 4 weeks. DL Ts of febrile neutropenia 
with bacteremia or sepsis were  only observed at 125 mg/m2 daily x5. Daily dosing achieved 
much better hypomethylation tha n the weekly regimen and the BED  of the daily regimen was 
established at 60 mg/m2 dailyx5. A t that dose there were no DLT s observed in Study SGI-110- 
01.
5 
 
2.2 Irinotecan 
   2.2.1 Background 
 
Irinotecan is an FDA approved, commercially available topoisome rase I inhibitor with activity 
against several solid tumor cell lines including colon, lung, a nd ovary. Irinotecan received an 
accelerated approval in June 1996 to treat metastatic cancer of  the colon or rectum that has 
recurred or progressed after s tandard therapy with 5-FU.  Irino tecan received full FDA approval 
in 1998 as a second-line treatment f or metastatic colorectal ca ncer. In April, 2000, irinotecan 
received accelerated approval fr om the FDA as first-line treatm ent for metastatic colon cancer 
when combined with 5-FU and Lec ovorin.   The cytotoxic effect i s due to double-strand DNA 
damage produced during DNA synthesis when replication enzymes i nteract with the ternary 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
7 complex formed by topoisomerase I, DNA, and either irinotecan o r SN-38 (its active 
metabolite).6  
 
2.2.2 Dose and Toxicology .   
 The drug is given intravenously w ith the MTD for weekly dosing being 125 mg/m
2 as a single 
agent.  The typical schedule of i rinotecan administration in me tastatic colon cancer is four 
consecutive weekly doses combi ned with 5-FU and leucovorin give n every six weeks.  
Conversion of irinotecan to SN- 38 (its active metabolite) occur s in the liver. Half-life for 
irinotecan is about 6 hours.  Half-life for SN-38 is about 10 h ours. SN-38 is 95% bound to 
plasma proteins.   
 
Irinotecan is associated with bot h early (during or shortly aft er infusion) and late (more than 24 
hours after infusion) forms of di arrhea that may be severe. Ear ly diarrhea may be accompanied 
by symptoms such as sweating, flu shing and abdominal cramping.  Late diarrhea can be 
prolonged, life threatening, and s hould be treated promptly. In  two Phase III tria ls in second line 
treatment of colorectal cancer , adverse events occurring more c ommonly in patients on 
irinotecan than best supportive care or 5-FU based therapy were  diarrhea, nausea, vomiting and 
neutropenia. In these studies , 60 percent of patients receiving  irinotecan were hospitalized at 
least once due to adverse even ts, compared w ith 63 percent rece iving best supportive care alone 
and 39 percent receiving 5-FU.  Pa tients also experienced tempo rary hair loss which usually 
returned after the completion of therapy.7   
2.3 Regorafenib 
 
2.3.1 Background of regorafenib 
Various signaling pathways have be en implicated in the developm ent and progression of 
colorectal cancer, involving receptor tyrosine kinases (eg, EGF R, VEGF receptor, platelet-
derived growth factor receptor [PDGFR], and fibroblast growth f actor receptor [FGFR]) and 
downstream signalling cascades (RA S-RAF-MEK-ERK and PI3K-PTEN-A KT-mTOR).8 
Regorafenib is a novel oral multikinase inhibitor that blocks t he activity of several protein 
kinases, including kinases involve d in the regulation of tumour  angiogenesis (VEGFR1 [also 
known as FLT1], VEGFR2 [KDR], VEG FR3 [FLT4], TIE2 [TEK]), oncog enesis (KIT, RET, 
RAF1, BRAF, and BRAFV600E), and the tumour microenvironment (PDGFR and FGFR).9 In 
preclinical studies, regorafeni b has shown antitumour activity,  including in colorectal cancer 
models.9 
In a phase 1b study, oral regoraf enib, given at a dose of 160 m g once daily for the first 3 weeks 
of each 4 week cycle, showed a tol erable toxicity profile and p reliminary evidence of antitumour 
activity in 38 patients with progre ssive colorectal cancer who had received previous therapy for 
metastatic disease (median four lines).10 The disease control rate (pa rtial response plus stable 
disease) was 74% (20 of 27 assessabl e patients). On the basis o f these results and the high unmet 
need in this population of patient s, the decision was made to p roceed to a randomized phase 3 
trial. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
8  2.3.2 CORRECT trial 
From Lancet: “CORRECT was a randomized, placebo-controlled, pha se 3 study involving 114 
centers in 16 countries in Nort h America, Europe, Asia, and Aus tralia. Patients were eligible to 
participate when they had histol ogical or cytological documenta tion of adenocarcinoma of the 
colon or rectum. They had to have r eceived locally and currentl y approved standard therapies 
and to have disease progression du ring or within 3 months after  the last administration of the last 
standard therapy or to have stopped standard therapy because of  unacceptable toxic effects. 
Patients were randomly assigned in a 2:1 ratio to regorafenib o r placebo. 
753 patients initiated treatment (regorafenib n=500; placebo n= 253; population for safety 
analyses). The primary endpoint of  overall survival was met at a preplanned interim analysis. 
Median overall survival was 6ꞏ4 mon ths in the regorafenib group  versus 5ꞏ0 months in the 
placebo group (hazard r atio 0ꞏ77; 95% CI 0ꞏ64–0ꞏ94; one-sided p =0ꞏ0052). Treatment-related 
adverse events occurred in 465 (93 %) patients assigned regorafe nib and in 154 (61%) of those 
assigned placebo. The most common  adverse events of grade three  or higher related to 
regorafenib were hand-foot ski n reaction (83 patients, 17%), fa tigue (48, 10%), diarrhoea (36, 
7%), hypertension (36, 7%), and r ash or desquamation (29, 6%).”11 
Based on these results, the FDA approved regorafenib for heavil y pretreated col orectal cancer 
patients on September 27, 2012.12 
2.4 TAS-102 (Lonsurf) 
2.4.1 Background of TAS-102 
For several decades, 5-FU was the only active chemotherapy in t he treatment of metastatic colon 
cancer.  Since then it, and othe r fluoropyrimidines, have remai ned the backbone to chemotherapy 
regimens for colorectal maligan cies.  Fluoropyrimidines act by inhibiting thymidylate synthase, 
which is necessary for the synthe sis of pyrimidine nucleotides and DNA synthesis.  TAS-102 is 
an oral combination of two agents:  trifluridine (thymidine-base d nucleic acid analog), which 
directly incorporates into DNA , and tipiracil hydrochloride (th ymidine phosphorylase inhibitor), 
which delays the breakdown of trifluridine.13 
 In a Japanese double-blind, random ized, placebo-controlled, pha se 2 trial of 169 patients with 
metastatic colorectal cancer  who had been heavily pretreated (t wo or more prior standard 
chemotherapy regimens) and were re fractory or intolerant to flu oropyrimidines, irinotecan, and 
oxaliplatin.  Patients were randomized in a 2:1 ratio to receiv e TAS-102 (35mg/m2) orally twice 
a day for 2-week cycle of 5 days  of treatment followed by a 2-d ay rest period, and then a 14-day 
rest period or placebo.  112 patient s were assigned to receive TAS-102 and 57 to placebo, with 
median overall survival of 9.0 months in TAS-102 group versus 6 .6 months in the placebo group 
(HR 0.56, 95% CI 0.39-0.81, p=0.0011).
14  A subsequent, internati onal Phase III trial was 
undertaken to evaluate the benefit.   
2.4.2 RECOURSE trial 
 RECOURSE was a randomized, placebo-controlled, phase 3 study in volving 116 centers in 13 
countries in North America, Eur ope, Asia and Australia.  Patien ts were eligible to participate if 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
9 they had biopsy-proven metastatic  colorectal ade nocarcinoma who  had received at least two 
prior regimens of standard chemo therapies with subsequent progr ession within 3 months after 
last administration of standard t herapy or intolerable side eff ects; or if patients had received 
adjuvant therapy, developed progr ession within 6 months.  Patie nts were randomly assigned in a 
2:1 ratio to receive TAS-102 or placebo.  798 patients initiated treatment (TAS-102 n = 533; placebo n = 265; intention to treat).  All 
patients had previously received fluoropyrimidine, oxaliplatin,  and irinotecan; 17% of the TAS-
102 group had previously received re gorafenib.  The primary end point of median overall survival 
was 7.1 months in the TAS -102 group and 5.3 months in the place bo group (HR 0.68, 95% CI 
0.58-0.81; p<0.001).  The median time to an ECOG performance st atus of 2 or higher was 5.7 
months in the TAS-102 group vers us 4.0 months in the placebo gr oup.  Treatment-related 
adverse events occurred in 524 (98 %) of patients receiving TAS- 102 and in 247 (93%) of those 
receiving placebo.  370 (69%) of TAS-102 patients had grade 3 o r higher adverse events, in 
comparison to 137 (52%) of those receiving placebo.  The most c ommon adverse events of grade 
three or higher related to TAS- 102 included neutropenia (38%), febrile neutropenia (4%), anemia 
(18%), thrombocytopenia (5%).  Hi gher grade three adverse event s for those treated with TAS-
102 compared to placebo were note d for nausea (2% v 1%), vomiti ng (2% v <1%), and diarrhea 
(3% v <1%).
15  Based on these results, the F DA approved TAS-102 for refracto ry metastatic 
colon cancer on September 22, 2015.16 
2.5 Study disease: colorectal cancer 
 
Metastatic colorecta l cancer (mCRC) is the second leading cause  of cancer death in the United 
States. In 2012, approximately 143,460 Americans will be diagno sed with CRC, and 51,690 will 
die from this disease.17 The five-year survival for all  patients with metastatic diseas e from CRC 
is only 8.1%.18 Median survival with current ge neration of chemotherapies, inc luding oxaliplatin 
or irinotecan as well as newer bi ologic therapies such as bevac izumab and cetuximab is only 20-
24 months. The only predictive biom arker that is currently used  in clinical colorectal cancer 
practice is KRAS  gene status which has only been i n clinical application since 2008 when mutant 
KRAS  was found to predict a lack of ben efit to anti-EGFR agents. Th erefore, there are currently 
only three lines of therapy for t he 40% of patients with KRAS m utation (oxaliplatin-based and 
irinotecan-based regimens) with a potential added option for KR AS wildtype patients.  
 Patients with mCRC have a 60%  likelihood of responding to first -line chemotherapy with an 
oxaliplatin or irinotecan cont aining regimen and drops to 10% i n the second line. Agents 
effective and or approved in the thi rd line such as panitumumua b and recently reported 
regorafenib have a less than 5% response rate, and an expected median overall survival of 6.4 
months.  However, in patients with  KRAS wildtype tumors who pro gressed on irinotecan, 
Cunningham et al. showed that retreatment with irinotecan with cetuximab resulted in a 22% 
response rate, and cetuximab is  now FDA-approved for this indic ation.  No such irinotecan 
retreatment option exists fo r KRAS mutated patients. 
 
   
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
10 2.6 Rationale 
 
Preliminary data from our group’s phase I/II study of 5-azaciti dine and entinosta t in non-small 
cell lung cancer has shown that, i n patients who received subse quent therapy with varied agents, 
approximately one third had at l east a partial response by RECI ST criteria to that subsequent 
therapy.19  In CRC, as there are no subse quent therapy options for patien ts after 2nd or 3rd line 
therapy (based on KRAS mutationa l status), our group has been e xploring the potential of 
DNMT inhibitor therapy to synerg ize subsequent therapy.  Ishigu ro et al. first demonstrated that 
treatment with DAC resulted i n gene re-expression of known tumo r suppressor genes in CRC; 
moreover, in both in vitro  and in vivo  models, DAC treatment subs tantially decreased tumor 
growth when combined with iri notecan or SN-38 (active irinoteca n metabolite) compared to 
either agent alone.20 In squamous cell cervical can cer, DAC restored SN-38 sensitivi ty in cells 
cultivated for SN38 resistance.21 5-aza has also been shown to inc rease irinotecan sensitivity i n 
multiple CRC cell lines, with a synergistic effect seen in a p5 3-mutated cell line.22 We have 
found that pretreatment of colorect al cancer cell lines with 5- aza or decitabine has sensitized 
CRC cell lines in vitro  to subsequent treatment with S N38, the active metabolite of ir inotecan, by 
both MTS and clonogenic a ssays (Figures 1-3).  
 
Figure 1 
  
 
Figure 1: CRC cell lines were trea ted in 96 well plates with az acitidine at 500 nM for 3 days fo llowed by two day exposure to 
SN38 and then analyzed by MTS assay. 
 
       

J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
11 Figure 2 
 
 
Figure 2: CRC cell lines were trea ted in 96 well plates with de citabine at 100 nM for 3 days fo llowed by two day exposure to 
SN38 and then analyzed by MTS assay. 
 
 
Figure 3 
 
Figure 3: 105 CRC cell lines were treated w ith decitabine at 100 nM for 3 da ys and then +/- SN38 
 
 We have seen similar effects i n a primary patient-derived xenog raft in vivo  (Figure 4). 

J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
12 Figure 4 
 
 
 
 
 Based on these data, we hypothesize that DNMTi therapy with SGI -110 will sensitize advanced 
colorectal cancer to treatment with Irinotecan. We propose a ph ase I study to assess the safety 
and tolerability of SGI-110 in com bination with standard irinot ecan therapy in 3
rd line + 
metastatic colon cancer, follo wed by a randomized phase II stud y to evaluate efficacy of the 
combination.   
 
3. PARTICIPANT SELECTION 
 
3.1 Eligibility Criteria 
 
3.1.1 Participants must meet the following criteria on screenin g examination to be 
eligible to participate in the study: 
 
3.1.2 Participants must have histologically or cytologically confirme d 
adenocarcinoma of the colon or rectum 
3.1.3 Patients in the phase I cohort mu st have biopsiable disease and  be 
amenable to having two research biopsies 
3.1.4 Archival tissue must be procured if available 
   
3.1.5 Participants must have measurable disease, defined as at least one lesion 
that can be accurately measured in at least one dimension (long est 
diameter to be recorded) as > 20 mm with conventional technique s or as > 

J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
13 10 mm with spiral CT scan. See se ction 10 for the evaluation of  
measureable disease.  
 
3.1.6 Patients in the phase II cohort must have progressed while rece iving 
irinotecan therapy in the metastatic setting.  There are no lim itations 
on number of prior therapies in the metastatic setting.  
 
3.1.7  Age minimum of 18 years.  
Because no dosing or a dverse event data are currently available  on the use of SGI-
110 in participants <18 years of age, children are excluded from th is study but will 
be eligible for future pediatric trials.  
3.1.8 Life expectancy of gr eater than 12 weeks. 
 
3.1.9 ECOG performance status <1 
  
3.1.10  Participants must have normal organ and marrow fu nction as defi ned 
below: 
 Leukocytes > 3,000/mcL 
 Absolute neutrophil count > 1,500/mcL 
 Platelets > 100,000/mcL 
 Total bilirubin < 1. 5X institutional upp er limit of normal 
 AST (SGOT)/ALT (SGPT) < 3.0 X i nstitutional upp er limit of norm al  
 with or without liver metastases 
 Creatinine < 1.5X insti tutional upper limit  of normal or creati nine 
clearance > 50 mL/min/1.73 m2 for subjects with cre atinine levels above 
institutional norm al                  . 
3.1.11   
The effects of SGI-110 on the d eveloping human fetus are unknow n. For this 
reason and because oncological age nts are known to be teratogen ic, women of 
child-bearing potential and men must agree to use adequate cont raception 
(hormonal or barrier method of birth control; abstinence) prior  to study entry and 
for the duration of study partic ipation. Should a woman become pregnant or suspect 
she is pregnant while participating in this study, she should i nform her treating 
physician immediately.    
3.1.12  Ability to understand and the willingness to sign a written inf ormed 
consent document.  
 
3.2 Exclusion Criteria 
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
14 3.2.1 Participants who exhibit a ny of the following conditions at screening will not be 
eligible for admi ssion into the study. 
 
3.2.2 Participants who have had chemotherapy or radiotherapy within 4  weeks 
(6 weeks for nitrosoureas or mito mycin C) prior to enrolling in  the 
study or those who ha ve not recovered from  adverse events due t o 
agents administered more than 4 weeks earlier. 
 
3.2.3 Participants may not be receiving any other study agents. 
 
3.2.4 Participants with known brain me tastases should be excluded fro m this 
clinical trial because of their poor prognosis and because they  often 
develop progressive neurologic dysfunction that would confound the 
evaluation of neurologic and other adverse events. 
 
3.2.5 History of allergic reactions a ttributed to comp ounds of simila r chemical 
or biologic composition to irin otecan, decitabine or SGI-110 . 
 
3.2.6 Subjects who have received prior therapy with any 
hypomethylating agents.  
 
3.2.7 Uncontrolled intercurrent illne ss including, but not limited to  ongoing or 
active infection, symptomatic cong estive heart fa ilure, unstabl e 
angina pectoris, cardiac arrhythmia, or psychiatric illness/social 
situations that would limit compliance with st udy requirements. 
 
3.2.8 Pregnant women are excluded fr om this study because SGI-110 is a/an 
hypomethylating agent with the potential for teratogenic or abo rtifacient 
effects. Because there is an unkno wn but potential risk of adve rse events 
in nursing infants secondary to tr eatment of the mother with SG I-110, 
breastfeeding should be discontin ued. These potential risks may  also 
apply to other agents used in this study  
 
3.2.9 Individuals with a history of a different malignancy are inelig ible except 
for the following circumstances : individuals with a history of other 
malignancies who have been disease-free for at least 5 years; o r 
individuals with another maligna ncy that are deemed by the inve stigator 
to be at low risk for clinically  meaningful recurrence (ex. cer vical cancer 
in situ , definitively treated early sta ge prostate cance r (confined to  prostate 
with Gleason 6 or below), defin itely treated breast ductal or l obular 
carcinoma in situ , basal cell or squamous cell carcinoma of the skin). 
 
3.2.10  HIV-positive individuals on combination antiretroviral therapy are 
ineligible , as these individuals are at increased risk of lethal 
infections when treated with mar row-suppressive th erapy. Appropriate 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
15 studies will be undertaken in participants receiving combination 
antiretroviral therapy when indicated  
 
3.2.11  Previous treatment with regorafenib AND TAS-102 (This applies t o phase 
II only.  If patients have previously received either regorafen ib OR TAS-
102, they must be able to receive the alternate regimen if rand omized to 
the standard of care arm) 
3.2.12  Hospitalization for an acute med ical issue within 4 weeks prior  to 
screening visit that would otherwise not be managed in an infus ion center 
or outpatient clinic setting (e.g., a patient admitted to compl ete a 
transfusion would not be ineligible.). 
3.2.13  Symptomatic bowel obstruction w ithin 6 months prior to enrollme nt. 
Patients who undergo surgical co rrection of obstru cting lesion will 
be eligible within 6 months 
 
3.3 Inclusion of Women, Minorities  and Other Underrepresented Popul ations  
 
Both men and women of all races and ethnic groups are eligible for this trial.  
 
 
4 REGISTRATION PROCEDURES 
   
4.1 General Guidelines 
 
 Eligible patients will be entered on study centrally at the Si dney Kimmel 
Comprehensive Cancer Center at  Johns Hopkins (SKCCC) by the Lea d Study 
Coordinator. A record of patients who fail to meet entry criter ia (i.e. screen failures) 
will be maintained.  Patient regis tration must be complete befo re beginning any 
treatment or study activities. 
 
Following registration, patients should begin protocol treatmen t within10 business 
days.  Issues that would cause t reatment delays should be discu ssed with the Principal 
Investigator.  If a patient doe s not receive protocol therapy f ollowing registration, the 
patient’s registration on the s tudy may be canceled.  The Lead Study Coordinator 
should be notified of cancellatio ns as soon as possible. 
 Except in very unusual circumstan ces, each participating instit utions will order SGI-
110 agents directly from Astex pharmaceuticals.  Agents may be ordered by a 
participating site only after t he initial IRB approval for the site has been forwarded to 
and acknowledged by the Coordinating Center. 
 
4.2 Registration Process 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
16  
To register a patient, the following documents should be comple ted by the research 
nurse or data manager and faxed to 410-502-0834, or emailed to the Lead Study 
Coordinator at tbrown55@jhmi.edu:   
 Copy of required laboratory tests  
 Signed patient consent form 
 HIPAA authorization form 
 Facsimile Transmittal Page 
 Completed Registration Patient Worksheet 
 Eligibility Checklist 
 To complete the registration pr ocess, the Lead Study Coordinato r will 
 assign a patient study number 
 assign the patient a dose 
 register the pa tient on the study 
 Fax or email the patient study number and dose to the participa ting site 
 Call or email the research nurse or  data manager at the partici pating site and 
verbally confirm registration  
 
4.3  Patient assignment and randomization procedure for second cohort  
Each subject who satisfies the eligibility criteria and is acce pted for the study will be 
assigned a unique identificati on number. The subject number wil l be used to identify the 
subject throughout the study and will be entered on all study d ocuments.  Once the subject 
identification number has been assigned, a confirmation email w ill be sent to all site 
personnel.  
For the Randomized Cohort, subjects will be randomized to each treatment arm (SGI-
110+irinotecan or regorafenib/TAS -102) prior to treatment admin istration and should not 
exceed 1 week of the planned dose. The assignment will not be b linded.  Randomization 
will be stratified by standard treatment (Regorafenib or TAS-10 2) and time from last 
irinotecan treatment (> 6 months or < 6 months) through a dynam ic algorithm to maintain 
balance between the arms as muc h as possible. For those assigne d to treatment arm with 
standard of care therapy will receive regorafenib (if previousl y received TAS-102) or 
TAS-102 (if previously received r egorafenib).  If they have nev er received either 
regorafenib or TAS-102, choice of therapy will be deferred to t reating physician and 
patient. 
This is an open-label study. There will be no blinding of treat ment assignment.  
 
5 TREATMENT PLAN
  
 
5.1 Overall Study Design 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
17  
There will be two stages in this study: A phase I lead-in (Stag e 1) followed by a randomized, 
controlled, open-label stage (Stage 2). Treatment will be admin istered on an outpatient basis 
 
5.1.2 Stage 1 
Stage 1 will be a traditional phase I study with a standard 3+3  design.23 A maximum of 
twenty-one eligible subjects will be enrolled to the phase I st udy.  Study drugs will be 
escalated per the schema to maximize the dose of drugs when giv en concurrently.  Patients 
will be treated with combined therapy immediately. Each cycle w ill last 28 days.  All patients 
enrolled at each dose level will be evaluated for DLT for the p urpose of determining the 
MTD.  The dose escalation scheme is shown below. 
         
  Table 2:  Dose escalation schedule  
Dose Level SGI-110 (SC) Irinot ecan (IV) Growth Factor Support w ith 
Filgrastim (or institutional equivalent) and/or Pegfilgrastim 
(SC) 
-1G 30 mg/m2 days 1-5 125 mg/m 2 days 8 and 15 each cycle Filgra stim 5mcg/kg/day Cycle 1 
Days 9-14 and peg-filgrastim 6mg D16, additional growth factor support during Cycle 1 and subsequent cycles per clinician 
judgment 
-1 30 mg/m2 days 1-5 125 mg/m2 days 8 and 15 each cycle Per cli nician judgment 
  1 (starting dose level) 45 mg/m 2 days 1-5 125 mg/m2 days 8 an d 15 each cycle Per clinician judgment 
1G 45 mg/m2 days 1-5 125 mg/m2 days 8 and 15 each cycle Filgras tim 5mcg/kg/day Cycle 1 
Days 9-14 and peg-filgrastim 6mg D16, additional growth factor support during Cycle 1 and 
subsequent cycles per clinician 
judgment 
2   60 mg/m2 days 1-5 125 mg/m2 days 8 and 15 each cycle Per cl inician judgment 
3  60 mg/m2 days 1-5 125 mg/m2 days 1, 8 and 15 each cycle Per clinician judgment 
 
 At least three patients will be treated at each dose level.  If  0/3 patients exhibits a dose-
limiting toxicity (DLT) after 4 weeks, the next patient will be  treated at the next dose level.  
If one patient exhibits a DLT related to the study agent(s), th e cohort will be expanded to up 
to 6 patients.  If 1 of 6 patients exhibits a DLT related to th e study agent(s), then the next 
patient will enroll at the next dose level.  If 2 of 3-6 patien ts exhibit a DLT related to the 
study agent(s), the MTD is considered to have been exceeded and  at least 6 patients will be 
entered at the dose level below the one at which DLT is defined . If this occurs on first dose 
level, the dose of SGI-110 will be reduced to 30 mg/m2 days 1-5  (Dose level -1). If no DLTs 
are encountered at Dose level -1, the next 3 patients will be e ntered at the next dose level, 
Dose level 1G. If one DLT is enc ountered at Dose level -1, this  dose level will be expanded 
to 6 total patients at Dose level -1. And if two or more DLTs a re encountered at Dose level 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
18 -1, at least an additional 3 patients will be enrolled at the l ower dose level, Dose level -1G. 
If 0/3 or 1/6 DLTs occur on Dose level -1G, the next 3 patients  will be dose escalated to 
Dose level 1G. If 2 or more DLTs out of 6 are experienced at Do se level -1G, the MTD will 
have been exceeded. Dose escalations will occur no sooner than 4 weeks after the last patient 
on the dose level has begun therapy to allow for full assessmen t of DLT.   
 Table 3:  Dose escalations schema  
Number of Patients with DLT 
at a Given Dose Level Escalation Decision Rule 
0 out of 3 Enter 3 patients at the next dose level. 
>2 Dose escalation will be stopped.  This dose level 
will be declared the maximally administered dose (highest dose administered).  Three (3) additional patients will be entered at the next lower  dose level if only 3 patients were treated previously at that dose. 
1 out of 3 Enter at least 3 more patien ts at this dose level. 
 If 0 of these 3 patients experience DLT, 
proceed to the next dose level. 
 If 1 or more of this group suffer DLT, then dose 
escalation is stopped, and this dose is declared 
the maximally administered dose.  Three (3) additional patients will be entered at the next lower dose level if only  3 patients were treated 
previously at that dose. 
<1 out of 6 at highest dose level 
below the maximally administered dose This is generally the recommended phase 2 dose. 
A t  l e a s t  6  p a t i e n t s  m u s t  b e  e n t e r e d  a t  t h e  recommended phase 2 dose. 
 Toxicity will be evaluated usi ng the NCI Common Terminology Cri teria for Adverse Events 
Active Version.  The frequency of toxicities per organ system w ill be tabulated using 
descriptive statistics. All patients who receive any amount of the study drug will be evaluable 
for toxicity. 
 
5.1.3 Stage 2 
The second stage of this study will be conducted as an open-lab el, randomized trial.
24 As of 
December 2015, the maximally tol erated dose from the phase I tr ial was determined at level 1G:  
 SGI-110 45mg/m2 SC D 1-5 
 Irinotecan 125mg/m2 IV D 8 and 15 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
19  Mandatory growth factor support during cycle 1: 
o Filgrastim (or inst itutional equivalent) 5mcg/kg SC C1 D 9-14 
o Peg-filgrastim 6mg SC C1 D16 
o Additional growth factor support dur ing Cycle 1 and subsequent cycles per 
clinician judgment 
Ninety-six eligible s ubjects will be randomized in a 2:1 ratio to receive either (1) SGI-
110+irinotecan combination treatm ent in 28-day cycles (n=64) or  (2) regorafenib 160 mg QD days 
1-21 in 28-day cycles or TAS-102 35mg/m2 BID days 1-5 and 8-12 in 28-day cycles as per 
physician choice (n=32). Safety data will be reviewed at least on a quarterly basis by the SRC. 
As epigenetic agents may take many months to show their benefit  as seen in MDS/AML 
studies,25 in both Stage 1 and Stage 2, subjects receiving SGI-110 + irin otecan may continue 
receiving their assigned treatment if their disease progresses based on RECIST criteria, 
version 1.1 if 1) the patient is  clinically stable, 2) the pati ent is informed of their scan results 
and agrees to continue therapy, and 3) the patient provider agr ees that remaining on study 
would be appropriate for the patient.  
Crossover to the SGI-110+irinotecan combination treatment arm o f the study will be permitted for 
subjects in the regorafenib/TAS -102 arm after there is evidence  of disease progression.  
Response and PFS will be evaluate d from images by the designate d investigators at each site. 
5.2 Screening and pre-treatment criteria 
 
5.2.1 Screening Procedures 
Screening procedures and tests will be performed within 14 days  before treatment administration 
with the exception of informed consent, tumor biopsy and radiol ogic response assessment which 
may be performed within 28 days of first dose of study drug. 
 Provision of written informed consent. The ICF must be signed a nd dated by the subjects before 
collection of any samples or performance of any study-specific evaluations.  
 Complete medical history, including demographics (date of birth , sex, race). A disease history, 
including the date of initial d iagnosis and list of prior treat ments and responses to these 
treatments, including time from last Irinotecan exposure (< or > 6 months), also will be 
recorded. Concurrent medical signs and symptoms must be documen ted to establish baseline 
conditions. 
 Record concomitant medications. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
20  Record all study-procedure related AEs from the time of informe d consent and then treatment-
emergent AEs after the start o f study drug administration (Cycl e 1, Day 1) through 30 days 
after the last dose of study drug.   
 Investigator’s confirmation of e ligibility. Perform all necessa ry procedures and evaluations to 
document that the subject meets each eligibility criterion. 
 Complete physical exam including weight and examination of the skin, eyes and fundi, ears, 
nose, throat, lungs, heart, abdomen, extremities, musculoskelet al system, nervous system, and 
genitourinary system.  
 Vital signs include resting syst olic/diastolic blood pressure, resting heart rate, resting 
respiration rate, body temperature and pulse oximetry. Assess a fter the subject has rested in 
the sitting position for at least three minutes.  
 ECOG performance status.  
 12-lead ECG (rhythm, atrial rate, ventricular rate, PR interval , QRS duration, and QT/QTc, 
morphology and overall interpretation). 
 Height. 
 Sample collection for clinical l aboratory tests (hematology, ch emistry and urinalysis).  
 Serum or urine pregnancy test: for female subjects of child-bea ring potential only. Results must 
be negative for the subject to be  eligible for enrollment into the study. 
 Tumor biopsies in all phase 1 subjects on study. Additionally, tumor biopsies will be collected 
on a select number of subjects in phase 2. The following sites:  SKCCC, VUMC, MSKCCC, 
and USC-Norris, will obtain biopsies on a total of 36 patients (distributed roughly evenly 
between the sites) for the first patients enrolled to the phase  2 if they have both biopsiable 
disease and are randomized to SGI-110 + Irinotecan. Optional bi opsies will also be requested 
of patients with base line research biops ies who remain on trial  through Cycle 6-9. 
 Radiologic response assessment. 
 CEA 
 Quality of Life evaluation at st art of study using the FACT-C q uestionnaire (Phase II only).   
   
5.2.2 Cycle 1, Day 1 
 
In order for patients to be treat ed, evaluations must meet labo ratory guidelines per the eligibility 
criteria 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
21 5.2.3  Cycle 1 Day 8, 15 an d Subsequent Cyc les, Day 1, 8, 15 
In order for patients to be treat ed, evaluations must meet the following criteria: 
 ANC > 1250 /mcL 
 Platelet count > 75,000 /cu mm 
 Bilirubin <2 mg/dL 
 Creatinine < 2 mg/dL 
 
5.3 Agent Administration  
 
5.3.1 SGI-110  
 
SGI-110 administered SC daily on Days 1-5.   Dose level for Pha se II is 45mg/m2 (modifications 
as per Section 6.3) 
SGI-110 is administered by SC injection preferably in the abdom inal area. The total amount (in 
mg) of SGI-110 to be administered will be determined based on t he body surface area (BSA). In 
calculating the BSA, actual heig hts and weights should be used.  There will be no adjustments to 
“ideal” body weight. The instituti onal standard for calculating  BSA is acceptable.  
The site(s) of SGI-110 SC injections will be captured on the do sing CRF. Additional guidelines 
regarding subcutaneous injection will be detailed in the SGI-11 0-02 Study Drug Reconstitution 
and Administration Manual.  
Investigators are prohibited fr om supplying SGI-110 to any subj ects not properly enrolled in this 
study or to any physicians or scie ntists except those designate d as sub-investig ators on Food and 
Drug Administration (FDA) Form 1 572. The investigator must ensu re that subjects receive SGI-
110 only from personnel who fully understand the procedures for  administering the study 
treatment. 
5.3.2 Irinotecan 
Irinotecan will be administered IV over 90 minutes at 125  mg/m2 per Table 3 (dose 
modifications as per Section 6.3).26 Cycles are 28 days long.  In cycle 1 irinotecan 
is given on days 8 an d 15 in dose levels - 1G, -1, 1, 1G, and 2,  and on days 1, 8, and 
15 for dose level 3. Patients who develop acute diarrhea second ary to irinotecan 
may receive atropine and/or sup portive measures per specific si te’s institutional 
standard.   
Irinotecan will be diluted in 5% Dex trose injection (D5W), USP (preferred) or 
0.9% Sodium Chloride Injection (NS), USP, to a final concentrat ion range of 0.12 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
22 to 2.8 mg/mL (D5W, or  NS). The drug will be administered intrav enously over 90 
minutes, or per institutional standards 
 
5.3.3 Regorafenib 
 
Patients randomized to non-experimental therapy arm who opt for  regorafenib, will 
be administered the agent as per standard dosing.27  Patients will take 160 mg once 
daily for days 1-21 of each 28 da y cycle. Patients will be inst ructed to take the drug 
with a low-fat breakfast and to take the pills whole (not crush ed). They will also be 
instructed to record drug intake on a patient pill diary (Appen dix B). 
 
5.3.4 TAS-102 
 
Patients randomized to non-experimental therapy arm who opt for  TAS-102, will be 
administered the agent as per standard dosing.  Patients will take  35mg/m2 (based 
on trifluridine component, w ith maximum si ngle dose 80mg ) twice daily for days 
1-5 and 8-12 of eac h 28 day cycle.16 Patients will be instructed to take the drug after 
breakfast and dinner and to take the pills whole (not crushed).  They will also be 
instructed to record drug intake on a patient pill diary (Appen dix C). 
 
 
5.4 Definition of Dose-Limiting Toxicity 
 
MTD will be defined based on the incidence of DLTs at each dose  level. 
Dose limiting toxicity is defined as any of the following occur ring through cycle 1 (Up 
t o  C y c l e  2  d a y  1 )  o f  t h e r a p y  r e l a t e d  t o  S G I - 1 1 0  o r  t h e  c o m b i n a t ion of SGI-110 and 
irinotecan. The DLT is defined using the Common Terminology Cri teria for Adverse 
Events (CTCAE).  
1. Hematologic toxicities deemed a DLT are:  
a. Grade 4 thrombocytopenia or ne utropenia lasting > 7 days. 
b. Any incidence of Grade 3 or 4 febrile neutropenia. 
2. Non-hematologic toxici ties deemed a DLT are:  
a. Grade ≥ 3 non-hematologic toxici ty unless it could be appropria tely 
managed by supportive treatment (e.g. hyperglycemia, nausea/vom iting, 
or diarrhea). 
b. Any other clinically significant adverse event which in the opi nion of the 
Safety Review Committee (SRC) would place subjects at undue saf ety 
risk, or results in discon tinuation of treatment. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
23 Dose-limiting toxicity (DLT) is based on the CTEP Active Versio n of the NCI 
Common Terminology Criteria for Adverse Events (CTCAE).28 
 
Management and dose modifications  associated with the above adv erse events are 
outlined in Section 6 (Expected Toxicities and Dosin g Delays/Dose Modifications) . 
 
5.5 General Concomitant Medication and Supportive Care Guidelines 
 
In general, concomitant medications and therapies deemed necess ary for the supportive care and 
safety of the subject are allowed, provided their use is docume nted in the subject records and on 
the appropriate case report form.  If toxicity occurs, the appro priate treatment per specific site’s 
institutional standard will be u sed to ameliorate signs and sym ptoms (including antiemetics for 
nausea and vomiting, anti-diarrheals for diarrhea and anti-pyre tics and anti-histamines for drug 
fever). All supportive m easures for optimal m edical care will b e given during t he period of study.  
5.5.1 Antibiotics  
Antibiotics may be utilized to prevent or manage febrile neutro penia based on institutional 
standard practice. Febrile neutropenia is defined as temperatur e at least 38.5ºC when the ANC is 
< 1000 µL. Febrile subjects shoul d be evaluated by physical exa mination, complete blood count 
(CBC) with differential, and blood culture. Subjects with febri le neutropenia or suspected sepsis 
on the basis of the physical examination are to be hospitalized  for appropriate broad spectrum 
antibiotic coverage, c onsistent with local  pathogen sensitiviti es.  
5.5.2 Hematopoietic Growth Factors 
Growth factor support is mandatory in cycle 1 for Phase II pati ents (Section 5.1.3).  Additional 
granulocyte-colony stimulating f actor (GCSF) may be administere d per ASCO guidelines from 
Cycle 1 onwards.29 Use of other white blood cell stimulating factors after Cycle 1 can be employed 
according to accepted practice or institutional guidelines, at the discretion of the treating physician. 
RBC transfusions can be adminis tered at the discretion of the t reating physician. 
5.5.3 Prohibited Medications 
The administration of any other anticancer agents including che motherapy and biologic agents is 
NOT permitted. Similarly, the use of other concurrent investiga tional drugs is not allowed.  
5.6 Duration of Therapy 
 
Duration of therapy w ill depend on individua l response, evidenc e of disease progression and 
tolerance. In the absence of treatment delays due to adverse ev ents, patients may continue on 
treatment until one of the fo llowing criteria applies: 
 Disease progression (for regoraf enib or TAS-102 arm in Phase II ), see 
below * regarding SGI-110 + irinotecan cohort. 
 Intercurrent illness that prevents further administration of tr eatment, 
 Unacceptable adverse event(s), 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
24  Participant demonstrates an inability or unwillingness to compl y with the 
medication regimen and/or documentation requirements 
 Participant decides to w ithdraw from the study, or 
 General or specific ch anges in the participant's condition rend er the participant 
unacceptable for further treatm ent in the opinion  of the treati ng investigator . 
*In both Stage 1 and Stage 2, subjec ts receiving SGI-110 + irin otecan may continue 
receiving their assigned treatm ent if their disease progresses based on RECIST 
criteria if 1) the patient is c linically stable, 2) the patient  is informed of their scan 
results and agrees to continue t herapy, and 3) the patient’s pr ovider agrees that 
remaining on study would be appropriate for the patient.  
 
5.7 Duration of Follow Up  
 
After removal from st udy, participants will  be followed every t hree months or 
sooner until death, whichever occurs first. Participants remove d from study for 
unacceptable adverse events wil l be followed until resolution o r stabilization of the 
adverse event.  Post-study case re port forms must be completed at least every three 
months until death and will capture information including subse quent treatments, 
response to subsequent therapy, and survival. 
  
5.8 Cross Over in Phase II  
 
As the primary endpoint of the Pha se II portion of this study i s PFS, patients who 
progress on standard of care tr eatment in phase II may crossove r to the study arm A. 
The minimum washout required per iod is 14 days from last dose.  Subjects will be 
followed for PFS, response, and survival as well as monitored f or toxicity. 
 
5.9 Criteria for Removal from Study Treatment   
 
Participants will be removed from study treatment when any of t he criteria listed in 
Section 5.6 applies. The reason f or study removal and the date the participant was 
removed must be documented in the study-specific case report fo rm (CRF). 
Alternative care options will be  discussed with the participant .   
 
In addition, a patient may be w ithdrawn by the investigator if he/she violates the study 
plan or for administrative and/ or other safety reason after dis cussion with the sponsor.  
When a subject discontinues/withdr aws prior to study completion , all applicable 
activities for the final study vi sit should be performed at the  time of discontinuation, 
including completion of the qual ity of life questionnaire FACT- C for subjects enrolled 
in the phase II portion.  Any advers e experiences which are pre sent at the time of 
discontinuation/withdrawal s hould be followed.  A follow-up off -study visit will occur 
within 30 days after last treatment. 
 If a patient withdraws for non-me dical reasons the following pr ocedures will be 
followed:    
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
25  Physical examination will be performed. 
 Safety assessment (physical exa mination, vital signs, hematolog y and serum 
chemistry), performed withi n 30 days after last treatment  
 
6 EXPECTED TOXICITIES AND DOSI NG DELAYS/DOSE MODIFICATIONS  
 
Dose delays and modifications wi ll be made using the following recommendations. Toxicity 
assessments will be done using the CTEP Active Version of the N CI Common Terminology 
Criteria for Adverse Events (CT CAE) which is identified and loc ated on the CTEP website at: 
http://ctep.cancer.gov/protocolDev elopment/electronic_applicati ons/ctc.htm .28  
 
If possible, symptoms should be managed symptomatically. In the  case of toxicity, 
appropriate medical treatment  should be used (including anti-em etics, anti-diarrheals, etc.). 
 
All adverse events e xperienced by participan ts will be collecte d from the time of the first 
dose of study treatment, throughout the study, and until the fi nal study visit. P articipants 
continuing to experience toxicity at the off study visit may be  contacted for additional 
assessments until the toxicity has resolved or is deemed irreve rsible. 
   
6.1 Anticipated Toxicities 
  
A list of the adverse events and p otential risks associated wit h the agents administered 
in this study appear below and wil l determine whether dose dela ys and modifications 
will be made and/or whether the e vent requires expedited report ing in addition  to 
routine reporting. Refer to the m ost recent versions of the ful l Prescribing Information 
for irinotecan (Camptosar
®), regorafenib (Stivarga®), TAS-102 (Lonsurf®) and the 
Investigator’s Brochure for SGI-110 for further information.1,7,27  
 
6.1.1 Adverse Event Lists(s) for regorafenib  
  
The most common adverse reactions ( 4 0 % )  w i t h  r e g o r a f e n i b  a r e  f a t i g u e ,  
hypocalcemia, hypophosphatemia, palmar-plantar erythrodysesthes ia, anorexia, 
diarrhea, transaminitis, hyperb ilirubinemia, anemia, lymphopeni a 
thrombocytopena, and proteinuria . Other adverse experiences (>1 0%) are 
hypertension, dysphonia, fever, pin, rash, hyponatremia, hypoka lemia, and 
infection. 
 
6.1.2 Adverse Event List(s) for irinotecan  
 
The most common adverse reactions ( 50%) with irinotecan are alopecia, anemia, 
thrombocytopenia, leukopenia,  hyperbilirubinemia, weakness, ano rexia, vomiting, 
and abdominal pain and cramping.  Other adverse experiences (>1 0%) are 
cholinergic toxicity (47%), feve r, dizziness, headache, chills,  constipation, 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
26 mucositis, weight loss, stoma titis, cough, dyspnea, rhinitis, a nd diaphoresis. Prior 
studies with irinotecan have reported neutropenia  and/or late diarrhea (diarrhea 
occurring more than 24 hours afte r irinotecan administration) a s the dose-limiting 
toxicities. The aggressive use of  loperamide can significantly decrease the 
incidence of severe delayed diarrhea. Other side effects includ e nausea, vomiting, 
anorexia, abdominal cramping, al opecia, anemia, and asthenia. A n immediate onset 
diarrhea may occur in the context of a cholinergic-like syndrom e which is 
characterized by diaphoresis, abdominal cramps, lacrimation, sa livation, and miosis 
or other visual disturbances. Ca ses of colitis complicated by u lceration, bleeding, 
ileus, and infection have been observed. Additionally, isolated  cases of pulmonary 
toxicity have been encountered. Finally, infrequent abnormaliti es of serum 
creatinine or hepatic enzymes, t hrombocytopenia, mucositis, or local irritation at 
infusion sites has been noted i n some patients. The use of irin otecan in the setting of 
liver dysfunction is currently under investigation. 
 
6.1.3 Adverse Event List(s) for TAS-102 
 
As per the RECOURSE trial, the m ost common adverse reactions (≥ 40%) are 
nausea, neutropenia, leukopenia,  anemia, and thrombocytopenia.  Other adverse 
experiences (>10%) include vomiting, diminished appetite, fatig ue, diarrhea, 
abdominal pain, fever, and asthenia. 
 
6.1.4 Adverse Event List(s) for SGI-110  
 
The most common AEs suspected by the investigators in Study SGI -110-01 to be 
related to the drug and observed to date in the MDS/AML populat ion are: injection 
site pain, fatigue, nausea, thrombocytopenia, anemia and diarrh ea. Based on the 
mechanism of action of the drug and its active form decitabine,  myelosuppression 
(neutropenia, thrombocytopenia, and anemia) and the related con sequences such as 
infection (e.g. pneumonia), seps is, and bleeding are the most l ikely risks for the 
drug. Mucositis has also been reported. The doses of SGI-110 be ing studied in this 
protocol (up to 60 mg/m2 dailyx5) have not been shown to cause drug-related 
myelosuppression when the drug is  used as a single agent. Howev er, in MDS/AML 
population it is difficult to asse ss the relationship to the st udy drug since most 
patients present with myelosuppr ession as part of their disease  condition. 
Preliminary safety data from an ongoing ovarian cancer trial in  combination with 
carboplatin showed significant ne utropenia and thrombocytopenia  when 45mg/m2 
SGI-110 days 1-5 is combined with  full dose of carboplatin (AUC  5).  
Pain and burning at the injecti on site has been reported that a re related to dose and 
volume of injection as well as t he speed of injection. Care mus t be taken to avoid 
intradermal injection. If injec tion site pain is reported upon injection, the practice 
of a slow injection (over 30-60 s econds), and the application o f ice packs to the 
injection site both before and after injection (a duration of 5 -10 minutes each is 
recommended) have been reported to attenuate the injection site  e v e n t s .  I f  t h e  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
27 injection site events are repor ted at subsequent injections des pite slow injection and 
the use of ice packs, pre-treatment with topical or systemic an algesics can be 
considered. 
 
6.2 Toxicity Management 
 
6.2.1 Irinotecan 
 
Patients who develop acute diarrhea secondar y to irinotecan may receive atropine 
and/or supportive measures per specific site’s institutional standard .  Patients will be 
monitored until symptoms abate.  Patients who experienc e new or worsening 
loose stools and/or diarrhea will be recommended loperamide (or  other 
equivalent anti-motility agent(s )) to take as directed followin g each loose 
bowel movement. Patients will be r egularly evaluated by the res earch nurse 
until resolution of the diarrhea . Either acute or chronic diarrhea could require 
hospitalization if the patient is  volume depleted or if other c linical symptoms warrant 
admission.  
If grade 2 or greater abdominal c ramping occurs, further chemot herapy will not be 
given until the cramping has fully resolved.  The patient will also be evaluated by the 
research nurse to determine the po ssible etiology of the crampi ng.  If cramping 
secondary to irinotecan is suspected, the treatment for abdomin al cramping will be 
equivalent to diarrhea (as stated above). 
 
6.3 Dose Modifications/Delays 
  
The Investigator should try to the best of his/her ability to a ssess whether an adverse event is 
possibly related to study treat ment, and if so, attribute it to  SGI-110 only, irinotecan only, or both 
SGI-110 and irinotecan, and treat the subject accordingly by on ly reducing the study drug that has 
most likely contributed to the individual toxicity necessitatin g dose reduction. This section 
provides suggested guidelines for the management of various stu dy drug-related toxicities in 
subjects receiving both SGI-110 and irinotecan. Preferably, onl y one study drug should be reduced 
at any one time even if both drugs are suspected to have contri buted to the toxicity (e.g. 
myelosuppression). SGI-110 should be  reduced first unless an ad verse event can most likely be 
attributed to irinotecan only (e.g., acute diarrhea or hyperbil irubinemia as they are not expected 
from SGI-110 treatment).  Lymphopenia of any grade that is asym ptomatic will not require dose 
modification. 
During Stage 2 of the study, subjects may be randomized to rece ive either regorafenib or TAS-102 
versus SGI-110 and irinotecan.  Dose modifications for regorafe nib or TAS-102 will be at the 
Investigator’s discretion and judgment per standard clinical pr actice and per most current FDA-
approved package inserts.  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
28 During Phase 2, treatment delays not related to adverse events (i.e. vacations) will be allowed 
beginning after cycle 4 for up to a period of 2 weeks at the di scretion of the Investigator, except if 
due to a holiday that cannot be avoided.   
 6.3.1 SGI-110 dose modifications In general, SGI-110 dosing should be withheld for Grade 4 myelo suppression or ≥ Grade 3 
SGI-110-related non-hematologic toxicities until toxicity has r esolved to ≤ Grade 1 or baseline 
levels. Treatment with SGI-110 may then be resumed at one dose level below the administered 
dose levels (i.e., 45 mg/m
2 if the patient received 60 mg/m2; or 30 mg/m2 if the patient r eceived 
45 mg/m2. One exception is neutropenia and anemia that can be m anaged by growth factors, and 
transfusion in subsequent cycles. In that case dosing may be re sumed at the same dose level. Dose 
reduction to less than 30 mg/m2 will not be allowed, and SGI-11 0 may not be omitted.  
If the subject has already received treatment with SGI-110 on D ay 1 or beyond, subsequent 
treatment days (Day 2-5 in the 5-day regimen) will be withheld if the subject d evelops any DLT 
and the skipped doses will be missed. Dosing will also be withh eld on Day 1 of any subsequent 
treatment cycles if the subject still has a DLT or other drug-r elated clinically significant toxicity 
that has not resolved to ≤ Grade 1 or baseline.  Dosing may res tart at a lower dose level once the 
subject becomes eligible again and the DLT or other drug-relate d toxicity has resolved to ≤ Grade 
1 or baseline. If dosing is delayed by more than 28 days becaus e of drug-related toxicity, then the 
subject will have SGI-110 perm anently discontinued and will be taken off of Arm A.  
6.3.2 Irinotecan dose modifications Irinotecan dosing should be withheld for ≥ Grade 3 irinotecan-r elated toxicities, and resumed 
depending on the timing of recovery and number of episodes occu rred (see Table 4 and 5). If 
irinotecan dosing is delayed due to irinotecan-related toxiciti es for > 2 consecutive  weeks despite 
supportive treatment per standard c linical practice and/or more  than 2 dose reductions of irinotecan 
is required, the subject should di scontinue irinotecan treatmen t but may be continued on SGI-110 
alone.  If both drugs cannot be restarted, the subject should b e withdrawn from the study and enter 
the 30-day follow up period.   
Table 4 below provides suggested g uidelines for the Investigato r to use along with his/her best 
judgment for SGI-110 and irinotecan dose delay and/or reduction  based on the AEs observed. If 
SGI-110 dosing is delayed due to SGI-110-related toxicities for  > 28 consecutive days despite 
supportive treatment per standard c linical practice and/or more  than 1 dose reduction of SGI-110 
and 2 dose reductions of irinotecan are required, stop SGI-110 and irinotecan therapy, discontinue 
the subject from the study, and complete the follow-up visit wi thin 30 days of the last 
administration of SGI-110 or irinot ecan, whichever is discontin ued last. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
29 Table 4: Dose Modification Gui dance for SGI-110 and Irinotecan for Selected 
Study Drug-Related Toxicities (Phase I) 
  Neutropenia or febrile neutropenia or anemia 
Occurrence Grade Dosing Guideline After Recovery t o Grade ≤ 1 o r baseline 
1st G 4 Treat anemia with transfusi on; Start GCSF prophylactically  in Cycle 2. No change in 
SGI-110 dose or irinotecan dose.  
2nd  G 4 Despite GSCF prophylaxis at ≥ Cycle 2, d ecrease SGI-110 d ose to 45 mg/m2 if previous 
SGI-110 dose was 60 mg/m2 or to 30 mg/m2 if previous dose was at 45 mg/m2.  
3rd  G 4  Continue SGI-110 at 30 mg/m2 but reduce irinotecan dose to 75% of previous dose. 
and continue GCSF prophylaxis 
4th  G 4 Discontinue subject from study 
Thrombocytopenia 
Occurrence Grade Suggested Action 
1st G  3  
G 4 No change in SGI-110  or irinotecan dose  
Reduce SGI-110 by one dose  level 
2nd  G 4 Despite SGI-110 dose reduction, decrease irinotecan dose to 75%  
3rd  G 4 Despite SGI-110 dose reduction, decrease irinotecan dose to 50% 
4th   G 4  Discontinue subject   
Transaminitis or Increased Creatinine 
Occurrence Grade Suggested Action 
1st ≥ G 3 No change in SGI-110 dose; reduce irinotecan by 25% 
2nd     ≥ G 3 Reduce irinotecan to 50% 
3rd >  G  3  Discontinue patient from study treatment 
 
Table 5: Dose Modification Gui dance for SGI-110 and Irinotecan with mandatory 
growth factor support for Selecte d Study Drug-Related Toxicitie s (Phase 
II) 
 
 
SGI-110 Dose Level 1G = 45mg/m2 D1-5, Irinotecan 125mg/m2 D8 an d 15,  filgrastim 5mcg/kg 
C1D9-14 and peg-filgrastim 6mg C 1D16 (further growth factor sup port in subsequent cycles at 
physician discretion) 
  Neutropenia or febrile neutropenia or anemia 
Occurrence Grade Dosing Guideline After Recovery t o Grade ≤ 1 o r baseline 
1st G 4 Treat anemia with transfusion;  
Decrease SGI-110 dose to 30mg/m2, or if alr eady reduced*, decre ase irinotecan to 75%
2nd  G 4 Decrease irinotecan dose to  75%, or to 50% (if previously  reduced to 75%) 
3rd  G 4 Decrease irinotecan dose to  50% from 75% or discontinue i f already reduced to 50% 
4th  G 4 Discontinue subject from study 
Thrombocytopenia 
Occurrence Grade Suggested Action 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
30 1st G  3  
G 4 No change in SGI-110  or irinotecan dose  
Decrease irinotecan dose to 75% 
2nd  G 4 Despite irinotecan dose re duction, decrease SGI-110 to 30 mg/m2 
3rd  G 4 Despite SGI-110 dose reduction, decrease irinotecan dose to 50% 
4th   G 4  Discontinue subject   
Transaminitis or Increased Creatinine 
Occurrence Grade Suggested Action 
1st ≥ G 3 No change in SGI-110 dos e; decrease irinotecan to 75% 
2nd     ≥ G 3 Decrease irinotecan dose to 50% 
3rd >  G  3  Discontinue patient from study treatment 
*SGI-110 cannot be dose reduced beyond 30mg/m2 
 
6.3.3 Dose modification for regor afenib or TAS-102 toxicities 
Patients randomized to regorafenib or TAS-102 treatment in phas e II of the study will have dose 
modifications at the Investigator’s discretion and judgment per  standard clinical practice and per 
most current FDA-approved package insert.    
7 DRUG FORMULATION AND ADMINISTRATION  
 
7.1 SGI-110 
 
7.1.1 Description  
 
Sodium (2 R,3S,5R)-5-(4-amino-2-oxo-1,3,5-triazin-1(2 H)-yl)-2 (hydroxymethyl) 
tetrahydrofuran-3-yl ((2 R,3S,5R)-5-(2-amino-6-oxo-1 H-purin-9(6 H)-yl)-3-
hydroxytetrahydrofuran-2-yl)methyl phosphate  
7.1.2 Form  
 
SGI-110 product is supplied in a  two-vial configuration. 
SGI-110 for Injection, 100 mg  is a 5 mL glass vial cont aining lyophilized SGI-110 
drug powder for reconstitution a nd subcutaneous injection using  the custom diluent 
supplied in a separate vial. Each  vial is stoppered with fluoro polymer coated butyl 
rubber closure and sealed with a blue flip-off cap. SGI-110 for Injection, 100 mg  
vial is individually packaged in a heat-sealed aluminum foil po uch with a single 
desiccant bag to protect from moisture. 
SGI-110 Diluent for Reconstitution, 3 mL or 1.2mL  is a 5 mL glass vial with 3 mL 
or 1.2mL of custom diluent. Each vial is stoppered with fluorop olymer coated 
butyl rubber closure and seal ed with a white flip-off cap.  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
31  
7.1.3 Storage and Stability  
 
SGI-110 for Injection, 100 mg  vial is stored at refrigerated condition of 2–8ºC in 
the original packaging until use. SGI-110 Diluent for Reconstitution, 3 mL can be 
stored at 2–30°C, and  1.2mL  can be stored at is store d at 2–8°C in upright position 
until use. Both vials are preservative-free and for single use only. SGI-110 must be 
stored in a secure, locked facili ty accessible only to authoriz ed study personnel. 
OSHA Guidelines for handling cytotoxic drugs outlined in the Am erican Journal 
of Hospital Pharmacy must be followed.26 As with other potentially toxic anti-
cancer agents, care should be exercised in the handling and pre paration of SGI-110. 
The use of gloves and protective garments is recommended. Prepa ration should 
occur in a vertical laminar flow biological hood using proper a septic technique. If 
SGI-110 contacts the skin, it shou ld be immediately be treated with borax buffer 
solution pH 10 followed by washing immediately and thoroughly w ith soap and 
water. If SGI-110 contacts the mucous membranes, flush thorough ly with water. 
Drug spilling can be inactivate d by 2 N sodium hydroxide soluti on.  
7.1.4 Handling  
 
Qualified personnel, f amiliar with procedur es that minimize und ue exposure to 
themselves and the environment , should undertake the preparatio n, handling, and 
safe disposal of the c hemotherapeutic agent in a self-contained  and protective 
environment.  
7.1.5 Availability  
 
SGI-110 is an inv estigational agent and w ill be supplied free-o f-charge from 
Astex Pharmaceuticals. 
 
7.1.6 Ordering and accountability  
 
An initial supply of SGI-110 will be shipped to each study cent er’s pharmacy when 
all the initiation documents, inclu ding IRB approvals and IRB a pproved ICF, have 
been received and reviewed by Astex Pharmaceuticals and upon ac tivation of the 
study center by the Coordinating Center JH SKCCC. Thereafter, i t is the 
responsibility of the trial pha rmacist to order a resupply. 
SGI-110 must be kept in a locked limited access room. The study  drug must not be 
used outside the context of the  protocol. Under no circumstance s should the 
Investigator or other study cen ter personnel supply SGI-110 to other Investigators, 
subjects, or clinics or allow supp lies to be used other than as  directed by this 
protocol.  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
32 An accurate accounting of the study drugs and investigational d evices must be 
maintained. These records must show dates, lot numbers, quantit ies received, and 
dispensed. SGI-110 accountability records must be maintained an d readily 
available for inspection by regul atory authorities at any time.  
7.1.7 Destruction and Return 
 
At the end of the st udy, unused supplies of SGI-110 should be d estroyed 
according to institutional policies. Destruction will be docume nted in the Drug 
Accountability Record Form.  
7.2 Irinotecan 
 
7.2.1 Description  
 This is an FDA approved chemoth erapy drug for the treatment of metastatic colon 
cancer.  It is also active in ot her diseases, namely other GI c ancers, lung and 
gynecologic malignanc ies.  Irinotecan (125  mg/m
2/w) will be administered IV.  It 
is commercially available. 
 
7.2.2 Form  
 
Irinotecan is commercially available. Vials contained 100 mg of  irinotecan as a 
pale yellow transparent solution in 5 mL total volume per vial.  Each milliliter of 
solution contains 20 mg of irinot ecan hydrochloride (on the bas is of the trihydrate 
salt), 45 mg of sorbitol NF pow der, and 0.9 mg of lactic acid, USP. The pH of the 
solution has been adjusted t o 3.5 (range, =3.0 to 3.8) with sod ium hydroxide or 
hydrochloric acid.  
  
7.2.3 Storage and Stability  
 
Intact vials are to be stored at controlled room temperature, p rotected from light until 
use.  Once diluted, the solution is physically and chemically s table for up to 24 
hours at room temperature (appr oximately 25C) and in ambient fl uorescent 
lighting.  Solutions diluted in 5%  Dextrose Injection, USP, and  stored at 
refrigerated temperatures (a pproximately 2 t o 8C), and protecte d from light are 
physically and chemically stabl e for 48 hours. Refrigeration of  admixture using 
0.9% Sodium Chloride Injection, U SP, is not recommended due to a low and 
sporadic incidence of visible particulates. 
7.2.4 Handling  
 
Qualified personnel, f amiliar with procedur es that minimize und ue exposure to 
themselves and the environment , should undertake the preparatio n, handling, and 
safe disposal of the c hemotherapeutic agent in a self-contained  and protective 
environment. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
33  
7.2.5 Availability  
 
Irinotecan is a standard of care, commercially available agent that is FDA –
approved for metastatic colorect al cancer. It is readily availa ble in oncology 
pharmacies at SKCCC and USC Cancer  Center and will be billed as  standard of 
care. 
7.3 Regorafenib 
 
7.3.1 Description  
The chemical name for regorafenib  is 4-[4-({[4-chloro-3-(triflu oromethyl) 
phenyl] carbamoyl} amino)-3fluorophenoxy]-N-methylpyridine-2-ca rboxamide 
monohydrate.  
 
Following a 160 mg dose of  regorafenib in pa tients with advance d solid tumors, 
regorafenib reaches a m ean peak plasma level (C max) of 2.5 μg/mL at a median 
time of 4 hours and a m ean area under the pl asma concentration vs. time curve 
(AUC) of 70.4 μg*h/mL. The AUC of r egorafenib at steady-state i ncreases less 
than dose proportio nally at doses greater  than 60 mg. At steady -state, regorafenib 
reaches a mean C max of 3.9 μg/mL and mean AUC of 58.3 μg*h/mL. The mean 
relative bioavailabil ity of tablets compar ed to an oral solutio n is 69% to 83%. 
 Regorafenib is highly protein bo und (99.5%) and is metabolized by CYP3A4 and 
UGT1A9. The mean (range) elimina tion half-lives for a single 16 0 mg dose of 
regorafenib and the  M-2 meta bolite in plasma are 28 hours (14 to 58 hours) and 
25 hours (14 to 32 hou rs), respectively. The  M-5 metabolite has  a longer 
mean (range) elimination half -life of 51 hours ( 32 to 70 hours) . Approximately 
71% of a radiolabeled dose was excreted in fec es and 19% of the  dose was 
excreted in urine (17%  as glucuronides) wi thin 12 days after ad ministration of a 
radiolabeled oral  solution at a  dose of 120 mg. 
 In vitro  studies with human hepatic micros omes or recombinant enzymes s howed 
that regorafenib and its metabolites competitively inhibit CYP2 C8, CYP2C9, 
CYP2B6, CYP3A4, CYP2D6, CYP2C19, UGT1A1, UGT1A9, BCRP, and P-glycoprotein.  Regorafenib is a substrate of  CYP3A4 and UGT1A9. In pharmacokin etic studies 
conducted in humans, mean regorafen ib AUC concentrations were i ncreased and 
decreased in the setting of c oncomitant admini stration with str ong CYP3A4 
inhibitors and induce rs, respectively. 
  
7.3.2 Form  
 
Regorafenib 40 mg tablet is the  only commercially available for mulation. It is pink 
and oval in appearance. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
34  
7.3.3 Storage and Stability  
 
Regorafenib tablets are supplied in packages containing three b ottles, with each 
bottle containing 28 ta blets for a total of  84 tablets  per pack age. Tablets must be 
stored in their original bottle. The desi ccant should not be re moved. Unused 
tablets should be discarded 28  days after openi ng the bottle in  accordance our 
chemotherapy waste policies.  Regorafenib should be stored at  25°C (77°F) with excursions per mitted from 15 
to 30°C (59 to 86°F). 
  
7.3.4 Availability  
 
Regorafenib is a FDA-approved, s tandard of care ag ent for metas tatic, pretreated 
colorectal cancer.  It will be provided thr ough standard Specia l Order Pharmacies 
and billed as sta ndard of care.    
 
7.3.5 Ordering  
 
Regorafenib will be ordered thr ough standard of care prescripti on and Specialty 
Order Pharmacies. 
7.4 TAS-102 (Lonsurf) 
  
7.4.1 Description  
TAS-102 (Lonsurf)  is an antitumor nucleo side drug tha t combines  FTD and 
TPI at a molar ratio of 1:0.5.  T he chemical name for TAS-102 ( Lonsurf) is 
trifluridine (α,α,α-trifluorothymidine) and tipiracil hydrochlo ride (5-chloro-6-[(2-
iminopyrrolidin-1-yl)methyl]pyrimidine-2,4-( 1H,3H )-dione monohydrochloride 
 As per the manufacturer’s guide:  “After twice daily dosing of L ONSURF, 
systemic exposure AUC of triflurid ine increased more than dose- proportionally 
over the dose range of 15 to 35 mg/m 2. After administration of LONSURF 35 
mg/m2 twice daily, the mean eli mination half-life (t1/2) of tri fluridine was 1.4 
hours and of tipiracil was 2.1 hours after a single dose. The m ean elimination 
half-life at steady state of t rifluridine was 2.1 hours and of tipiracil was 2.4 hours. 
The accumulation of trifluridine wa s 3-fold for AUC0-last and 2 -fold for peak 
plasma concentration (Cmax) at steady state while no accumulati on was observed 
for tipiracil. Administration of a  single dose of LONSURF conta ining tipiracil and 
trifluridine 35 mg/m2 increased  the mean AUC0-la st of triflurid
ine by 37-fold and 
Cmax by 22-fold with reduced variab ility compared to trifluridi ne 35 mg/m2 
alone.   
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
35 Following a single oral adminis tration of LONSURF at 35 mg/m2 i n patients with 
cancer, the mean time to peak plas ma concentration (Tmax) of tr ifluridine was 
around 2 hours.   A standardized high-fat, high-ca lorie meal decreased trifluridi ne Cmax, tipiracil 
Cmax and AUC by approximately 40% , but did not change triflurid ine AUC 
compared to those in a fasting sta te in patients with cancer fo llowing 
administration of a single dose of LONSURF 35 mg/m2. It is reco mmended to 
take LONSURF within 1 hour after  completion of the morning and evening meals 
based on the observed correlation be tween the increase in the C maxof trifluridine 
and the decrease in n eutrophil counts.  
 Trifluridine mainly binds to huma n serum albumin. The in vitro protein binding 
of trifluridine in human plasm a is greater than 96%, independen t of drug 
concentration and presence of tip iracil. Plasma protein binding  of tipiracil is 
below 8%  Trifluridine and tipiracil are not  metabolized by cytochrome P4 50 (CYP) 
enzymes. Trifluridine is mainly eliminated by metabolism via th ymidine 
phosphorylase to form an inactiv e metabolite, 5-(trifluoromethy l) uracil (FTY). 
No other major metabolites were detected in plasma or urine.  Following a single dose of LON SURF at 60 mg, the mean 48-hour c umulative 
urinary excretion was 1.5% for  unchanged trifluridine, 19.2% fo r FTY, and 29.3% 
for unchanged tipiracil.”  
7.4.2 Form  
 
TAS-102 is formulated as an immediate-release film-coated table t, which is 
supplied in strengths (ex pressed as FTD content): 
• The 15-mg white, round tablet contains 15 mg FTD and 7.065 mg T PI as 
active ingredients. 
• The 20-mg pale-red, round table t contains 20 mg FTD and 9.42 mg  TPI as 
activeingredients. 
 Both tablet strengths contain lactose monohydrate, pregelatiniz ed starch, stearic 
acid,hypromellose, titanium dioxide , polyethylene glycol, and m agnesium 
stearate. The 20-mg tablet for TAS-102 also contains red ferric  oxide. 
 
i. Storage and Stability  
 
TAS-102 cards must be stored at room temperature between 59°F a nd 86°F (15°C 
and 30°C). 
  
ii. Availability  
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
36 TAS-102 is a FDA-approved, standar d of care agent for metastati c, pretreated 
colorectal cancer.  It will be provided thr ough standard Specia l Order Pharmacies 
and billed as sta ndard of care.    
 
iii. Ordering  
 
TAS-102 will be ordered through standard of care prescription a nd Specialty 
Order Pharmacies. 
8 CORRELATIVE/SPECIAL STUDIES  
 
A unique patient identifier will  be assigned to each patient by  the coordinating center.  The 
same unique patient identifier li nked to the tumor biopsies wil l be used to shield the 
archived blood samples. The protoc ol scientific investigator(s)  handling the samples will be 
blinded as to the patient iden tification, patient data and outc ome. 
Research bloods and biopsies will  be batched and sent to Dr. Ah uja’s laboratory at the 
conclusion on enrollment for the study as described in this sec tion. 
 After shipping, samples and associ ated data will be stored at J ohns Hopkins unless the 
patient withdraws consent. 
 
Up to two sources of tumor DNA (blood and tumor biopsies) will be evaluated for DNA 
methylation status in each patient.  Blood will be drawn from a ll patients in the study prior 
to starting treatment, as well as on days 8, 15, and 22 of the study for Cycle 1.  For the 
subsequent cycles, blood will be  collected prior to reconvening  treatment on Day 1 and 15 
(as well as on day 8 of cycle 2), for  patients on Arm A. On Arm  B, cycles 1 and 2, samples 
will be collected on days 1 and 15. S ubsequent cycles (Cycle 3 and beyond) correlative 
samples will be collected  on day 1 of a cycle.  The blood sampl es will be used to assess the 
methylation status of free tumo r DNA circulating in the blood. Tumor biopsies will be 
performed on all patients prior to starting treatment and post- treatment biopsies will be 
obtained prior to treatment ( Cycle 1 Day1), and on ~ Cycle 1 Da y 8 in Phase I and cycle 2 
Day 8-15 for patients selected for  biopsy in Phase II, and at t he conclusion of the trial 
(optional).Methylation status will be assessed pre- and post-tr eatment.  In those patients who 
have evidence of methylation c hanges comparing pre and post tre atment analyses, further 
confirmatory studies will be done  to assess if t hese changes in  methylation correlate with 
gene re-expression.  
 
Methylation-specific PCR (MSP) w ill be used to detect the prese nce of methylated alleles 
for specific genes described below.
30-34 Genes found to be methylat ed in pre-treatment 
specimens will be monitored for post-treatment changes in methy lation using MSP. 
Methylation analysis may the n be performed by using a nested MS P approach. The nested 
MSP approach has a sensitivity of 1 in 50,000 methylated allele  to determine the genes that 
are methylated amongst the panel for each patient. A non-nested  real-time MSP approach 
will then be used to follow the biologic response across variou s time points in the study for 
the genes of interest. This strategy of nested MSP followed by non-nested MSP has been 
validated in the ongoing study in t he MDS/AML patients using bo ne marrow specimens as a 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
37 useful monitoring tool fo r biologic response. 
 Patients will have plasma samples  analyzed for DNA methylation patterns pre-treatment as 
well as on Days 8, and 15 and 22 for Cycle 1. For the subsequen t cycles, blood will be 
collected prior to reconveni ng treatment on Day 1 and 15 (as we ll as on day 8 of cycle 2), 
for patients on Arm A. On Arm B, cycles 1 and 2, samples will b e collected on days 1 and 
15. Subsequent cycle (Cycle 3 and b eyond) correlative samples w ill be collected on day 1 of 
a cycle.  Candidate genes that will be analyzed for promoter me thylation include potentially 
(but not limited to): p16, SFRP 1, TFPI-2, IGFBP3, O6-MGMT, APC, CHFR, RASSF1A, 
WRN, DR1, and hMLH1 . Genes found to be methylated in pre-treatment specimens will be 
monitored for post-treatment changes in methylation using quant itative MSP. DNA will first 
be extracted from plasma using t he Methylation-On-Beads (MOB) t echnology, a novel 
nano-based methodology designed to capture extremely low quanti ties of blood found in 
blood.
34-35  Serum-based methylation analy sis has been performed and repor ted previously 
using a variety of approaches.36-38 In previous studies, this na no-enabled assay demonstrated 
high sensitivity for s creening of common cancers such as lung a nd colorectal and points to 
the enormous potential of using t his platform for surveillance of responses to epigenetic 
therapy.  The utility of the nano-enabled platform will be expl ored in the ongoing 
correlative studies to develop a  sensitive assay for detection of response to epigenetic 
therapy. Methylation analysis will then be performed by using a  quantitative MSP approach. 
8.1 Archival tissue 
 
We will consent patients to obtain paraffin-embedded blocks of prior tissues including 
their primary cancer, if possibl e. This will allow us to perfor m methylation analysis on 
primary tumors, and determine if the primary and metastatic les ions have a similar 
profile.  DNA will be extracted a nd analyzed similar to the tre atment for tumor biopsies 
above. Expression analysis will a lso be performed in selected c ases, as feasible. 
 Archival tissues will be requested for each patient from all pr ior surgeries. Paraffin 
blocks containing tumor sections  will be requested. Par affin blocks must be 
confirmed by the pathologist to contain primary tumor. These bl ocks must be sectioned 
to generate a total of 10 curls of  10 micron thickness. These c urls should be placed in 
two 2ml eppendorf tubes with 5 c urls in each. The eppedorf tube s must be clearly 
labeled with the Patient ID, date  from which the primary tumor was collected (date of 
surgery), and appropriate pathol ogy report for th e block will b e requested. Additionally, 
one stained hematoxylin and eosi n slide (H&E) and two unstained  plus slides should be 
created from the same blocks.  The se slides must be labeled wit h the Patient ID, and the 
date of surgery as above. 
 
8.2 Pharmacokinetic Studies 
 
Pharmacokinetic evaluation will be conducted during Phase 1 onl y, in all subjects in order to 
evaluate exposures of SGI-110 a nd decitabine in the disease pop ulation. SGI-110 does not inhibit 
nor induce CYP3A4, whic h is the major contributing enzyme to ir inotecan metabolism. As such, 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
38 irinotecan pharmacokinetics will no t be evaluated in this study  as its exposures are not expected 
to be affected by SGI-110.  Pharmacokinetics of SGI-110 and de citabine will be assessed fro m plasma concentrations.  
Plasma samples will be prepare d from blood drawn at the followi ng time-points: 
Cycle 1, Day 1: pre-dose, 15 m in, 30 min, 60 min, 90 min, 2 hr,  4 hr, 6 hr and 8 hr post-dose. 
Sampling windows are up to 10% of pr otocol specified time point  but no more than 1 hour.  
Details for procedure for PK sam ple collection are included bel ow. 
Plasma samples will be appropria tely labeled and shipped for an alysis to: 
 Nabeela Aleem, Sample Coordinator Frontage Laboratories, Inc. 700 Pennsylvania Drive   
Exton, PA 19341 P: 484-348-4790 Email : <naleem@frontagelab.com> 
 
Procedures: A. Preparation of K2EDTA Vacutain er tubes containing THU (tetra hydrouridine) 
Materials— 
THU: Calbiochem 584222, E MD Chemicals, Inc. 
 
Notes and Preparation of THU: 
1. The BioVision, Inc datasheets i ndicate that the 10 mg vial of T HU must be stored frozen 
and protected from light at –20°C . The material is hygroscopic and difficult to weigh, and 
reconstitution of the entire cont ents at the intended concentra tion is strongly suggested. 
2. Following reconstitution in water  (do not use methanol), aliquo ts can be purged with 
nitrogen and frozen at –20°C. T he datasheets indicate that thes e aliquots are stable for up 
to 3 months at –20°C. 
3. Prepare a 0.4 mg/mL solution of T HU. Since the datasheet purity  of THU is listed as 
>80% (by TLC), assume that there are 8 mg of THU per vial of TH U. Diluting this to a 
volume of 20 mL in a graduated c ylinder or grad uated centrifuge  tube gives a 0.4 mg/mL 
(400 ug/mL) solution of THU. K eep this solution on ice. 
 Measure a volume of 10 ml of ster ile water into a graduated cyl inder or a 50 mL 
graduated  centrifuge tube 
 Use a serological pipette to a dd approximately 1 ml of water to  the vial of THU. 
 Mix/shake the THU vial as best  as possible, until the powder se ems to be 
dissolved in the water. 
 Transfer the liquid from the T HU vial into the graduated cylind er or graduated 
centrifuge tube 
 Bring the total volume of  the container to 20 ml. 
 
Preparation of Vacutainer tubes: 
1. Pop the top of the vacutainer t ube to break the vacuum seal. 
2. Using a pipettor, immediately d eliver at least 20 uL (20-30 uL)  of the THU solution into 
each of the labeled K2EDTA 6 mL Vacutainer tubes. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
39 3. When all K2EDTA Vacutainer tubes have been prepared with the TH U and labeled, store 
the tubes refrigerated for up to 30 days. 
4. Toss the THU aliquot remainder when done. 
 
B. Plasma Sample Collection: 
Note: Blood samples for PK studi es need to be processed immedia tely. It is imperative that the 
following procedures be followed aft er collection of the sample  to stabilize th e drug and its 
various metabolites. 
1. Using a syringe, collect a 6 mL  peripheral blood sample and tra nsfer to the 6 mL 
K2EDTA tube preloaded with THU and stored at 4°C. 
2. Immediately upon collection, mi x the blood sample by gently inv erting the tube 8-10 
times and then immediately place the tube in a container of wet  ice. Samples must be 
kept on the wet ice until centr ifuged. Use wet ice to avoid sam ple hemolysis. 
3. Centrifuge the EDTA tube, pre- loaded with THU , at either 1800 g  x 10 min at 4°C or 
1500 g x15 min at 4°C. The tube sh ould be centrifuged within 1-  2 hours of collection. 
4. Immediately after centrifugati on, use the pipette s provided to transfer at least 1.0 mL of 
plasma into each of 2 labeled scr ew top tubes and store in a –2 0°C freezer until shipment. 
5. Store the samples for a minimum of 8 hours at –20°C until packa ging for shipment to 
Frontage Labs. Samples should be shipped to Frontage for analys is within 90 days of 
collection, if possible. 
6. Samples should be packaged for shipment in triple packaging, se aled and cushioned and 
containing sufficient amount of c rushed dry ice to last the dur ation of transport.  
  PK Specimen Collection guide 
 
 
 
8.3 Pharmacodynamic Studies 
8.3.1 Tumor Biopsies 
Mandatory tumor biopsies will be r equired at baseline and on Cy cle 1 Day 8 in the 
phase I cohort. Tumor biopsies at baseline and during Cycle 2 ( between C2D8 and 
C2D15)   will also be collected f rom the first 36 patients enro lled in the phase II 
cohort with biopsiable disease randomized to SGI-110 + Irinotec an (Arm A) 
approximately evenly spread betwee n the following study sites: SKCCC, VUMC, 
MSKCCC, and USC-Norris. Core biopsies are required;  4-6  passe s must be 
obtained. Fine needle aspiration biopsies may be allowed only a fter PI approval. 
Pre- and post- biopsy should be pe rformed from same organ site.  For example: if 

J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
40 pre- biopsy is liver, then post- biopsy should also be liver an d preferably the same 
lesion. Biopsy sites (liver, colon, intra-abdominal implants) i n metastatic colorectal 
cancer are generally amenable to biopsy, and pre- and post-trea tment tissue 
sampling is an important strengt h of this study. Post-treatment  biopsies will be done 
~cycle 1 day 8 (and between C2D 8 and C2D15 during the phase II portion of the 
study).The timing of the post-treatment biopsy will be performe d based on prior 
experience in the leukemic patient s where the majority of demet hylation events 
have been seen at between 8-15 days of each cycle.  Patients wi th baseline biopsies 
who remain on the trial beyond 6 c ycles will be asked to partic ipate in another 
research biopsy between cycles 6-9.   
There was no comparable data in solid tumors. All biopsy specim ens will be stored 
as fresh tissue at least -70°C for extraction of DNA and RNA. B iopsy specimens 
will be studied for tumor methyl ation profiles, as described be low. Evaluation of 
expression of genes that become d emethylated post-treatment wil l be performed 
using quantitative real-time PC R and/or expression arrays. If a n attempt at biopsy is 
unsuccessful, the patient will s till be eligible for treatment and the subsequent 
biopsies will be foregone. Tumor bi opsies and plasma from the p hase I portion of 
the trial will be analyzed prior  to moving onto p hase II for de methylation and the 
timing of the biopsies in the ph ase II component of the trial m ay be adjusted based 
on these results.  As of Decemb er 2015, our Phase I data showed  no clear pattern in 
demethylation at C1D8, while serum demethylation appeared to ha ve a delayed and 
dose-dependent nadir in the middle of cycle 2, therefore timing  of the second 
biopsy was move d to C2D8-15. 
 Tumor Biopsy Processing 
 Prior to initiation of therapy, t umor samples will be collected  by direct or 
ultrasound-guided core biopsy from accessible tumor tissue. A m aximum of 6 
core tissue samples will be obtained from each patient. Core bi opsy is preferred 
and FNAs are only to be done when c ore biopsy is not safe (such  as with lung 
lesions). There are 4 parts to t he procedure: preparation, slid e creation, dry 
protocol, and RNAl ater protocol. Biopsies must be flash f rozen within minutes 
of biopsy collection, and immedi ately stored at -70C or below. Biopsies may 
be batched and shipped at the e nd of this study to Dr. Nita Ahu ja’s 
laboratory as detailed in this p rotocol. DO NOT ship biopsies o ut on 
Thursday or Friday to prevent week end arrival; shipment should occur the 
following Monday. All samples, blood and biopsies MUST BE OVERN IGHT 
EXPRESSED to ensure next day delivery. When preparing for shipm ent, fill 
an insulated styrofoam box with DRY ICE (NOT ICE), enough to fi ll at least 
¾ of the box. This will ensure th at plenty of dry ice remains d uring the 
duration of the delivery process to protect the quality of the specimens.  Fill 
half the box with DRY ICE, pla ce the specimens in the middle, a nd fill up to 
top with DRY ICE.  
 
a. CORE BIOPSY PROTOCOL 
i. Preparation: 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
41 1.Prepare a 50:50 mixture of dry ice and isopropanol mixture in  a 
styrofoam bucket to a depth of  1 inch.  A liquid nitrogen bath is also 
acceptable. 2. Label 5 cryovials with Patient  ID, Cycle/ Day, Specimen Type  (biopsy, 
location), and Date  of collection.  
3.Fill one of the vials with 1mL  RNAlater and add RNAlater desi gnation 
on the tube.  
ii. Slide creation: 
1. The first biopsy passage should be  used for the creation of an H&E or 
cryoslide which an onsite pathologist will use to confirm the b iopsy is 
tumor tissue. a. If it is not possible to obtai n an onsite pathologist, please c reate an 
H&E slide and send to Dr. Nita Ahuj a’s laboratory for analysis 
b. After the pathologist’s confir mation, keep and store slides at room 
temperature and send to Dr . Nita Ahuja’s laboratory. 
 
iii. Dry protocol: 
1.During each of the subsequent pa sses, transfer each biopsy to  an 
enclosed empty 1.8mL cryovial  (Use sterile techniques) 
2.Flash freeze each vial immedi ately by adding the cryovial to the 50:50 
mixture in the bucket or i n the liquid nitrogen. 
 
iv. RNAlater protocol: 
1. On the last passage, add a core b iopsy to the cryovial filled w ith 
RNAlater and flash freeze by i mmersing the tube in the 50:50 
mixture or liquid nitrogen. 
a. NOTE: RNAlater is NOT sterile and needle dipped in this 
solution should not be reused on the patient  
2. Samples will be stored at or below -70C until shipped to Dr. Ni ta 
Ahuja via overnight express in DRY ICE. ADD ENOUGH DRY ICE 
TO FILL AT LEAST ¾ OF THE INSULATED SHIPPING BOX. Biopsies may be batched and shippe d at the end of this study to  Dr. 
Nita Ahuja’s laboratory. Avoid s hipping on Thursdays and Friday s to 
prevent weekend arrival. Store in -70C or below until following  
Monday to ship for Tuesday arrival. 
 
 
b. FNA PROTOCOL 
There are 3 steps to this protoc ol: preparation, s lide creation , and saline 
protocol.  
i.Preparation 
1.Prepare a 50:50 mixture of dry ice and isopropanol mixture in  a 
Styrofoam bucket to a depth of  1 inch. A liquid nitrogen bath i s also 
acceptable. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
42 2.Label 5 cryovials with patient i dentification, d ate of collec tion, 
Cycle/Day, and specimen t ype (biopsy location.) 
3.Add 1mL of saline to each tube.  
ii. Slide Creation 
1.Perform the first FNA biopsy pass 2.Create an H&E slide or Cryoslide 3.Have an onsite pathologist conf irm the sample is of tumor. 
a. If an onsite pathologist is not ava ilable, please send the slid es to 
Hopkins for analysis b. Keep the slides at room temperature 
 
iii. Saline protocol: 
1. Transfer subsequent FNA aspirate  to separate cryovials  filled with 
saline. 
a. Inject and swish the c ells into the saline 
2.Flash freeze the cells immediately by immersing cryovials to the 50:50 
mixture in the bucket. 3.Samples are to be stored at -70C. 
4.When shipped, the samples shoul d be shipped overnight express i n 
enough DRY ICE to fill  at least ¾ of the box.  
 
8.3.1.1  Methylation analysis 
 
Genome-wide methylation analysi s will be performed using the In finium Illumina 
based assay that allows methyl ation analysis of >450,000 CpG si tes covering 
greater than 14,000 genes.
 Beta values indicating methyl ated CpG islands will be 
isolated.  Pre- and post-treatment  biopsies will be compared to  determine genes 
that demethylated following tre atment. Cannonical tumor suppres sor genes will 
be closely scrutinized for CpG  island methylation.  These resul ts will then be 
correlated with expression values.  Methylation patterns in the prom oter regions of selected tumor suppressor genes 
will be determined using quantitat ive real time nested Methylat ion Specific PCR 
(MSP). This technology is ideally  suited for increasing the thr oughput of PCR 
analysis and gaining a level of  quantification not possible wit h the standard MSP 
analysis. DNA will be isolate d from blood, and tumor biopsies a nd treated with 
sodium bisulfite under denaturing conditions (123). Bisulfite m odified DNA from 
each post treatment specimen will be analyzed for changes in DN A methylation at 
specific gene promoters (to inc lude p16, SFRP1, IGFBP3, TFPI2, RASSF1A, and 
mlh1). PCR primers for these ha ve been described and are in fre quent use in the 
Ahuja lab.   For each gene, separate PCR reactions will be performed with me thylated-specific 
primers and unmethylated specifi c primers (as used in conventio nal gel based 
MSP analysis).  Each reaction wi ll be run in triplicate. A sepa rate PCR reaction 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
43 will utilize primers specific for the unmethylated promoter reg ion of the beta-
actin gene, a gene necessary for  normal cell structure and func tion, which has 
never been observed to be met hylated in any cancer. Real-time c urves for the 
MSP reaction will be compared to the unmethylated reaction and to the beta-actin 
control. Mixing experiments util izing DNA from cell lines methy lated at a given 
locus and a completely unmethylated DNA source (normal DNA) wil l be 
performed to determine accurac y of quantification. Assays will be performed on 
the Bio-Rad I-cycle. Two methods  of detection will be compared:  non-specific 
quantification of PCR products us ing Syber Green, and specific detection using 
molecular beacons. A ratio of the  inverse of the cycle threshol d for the methylated 
gene of interest over the invers e of the cycle threshold for be ta-actin will be 
calculated. This ‘methylation index’ will be compared pre- and post-treatment.   
 If changes in methylation patter n are observed by MSP, this res ult will be further 
validated by bisulfite se quencing of selected genes 
 8.3.1.2   Expression analysis   The goal of DNA methyltransferas e inhibition is reversal of tra nscriptional 
inhibition due to repressive ch romatin conformation related to hypermethylation 
and changes in histone tails along with changes in miRNA. Given  the 
heterogeneity of metastatic color ectal cancer the selection of specific genes to be 
studied across patient samples is challenging. Evaluation of ex pression of genes 
that become demethylated post-trea tment will be performed using  quantitative 
real-time PCR, whenever possibl e. Gene re-expression will be st udied also using 
genome wide strategies using quan titative PCR using the Amplifl our if additional 
funds are available. Universal a mplification and detection syst em (Intergen). This 
system has the advantage of the use of multiple fluorophores fo r each gene (up to 
four fluorophores can currently be  analyzed). RT-PCR used semi- quantitatively 
will be combined with real-time  quantification using the ABI 77 00 system within 
the Johns Hopkins Oncology Center. Beta-actin will be used as a  control.  
Expression will be reported as a ratio of gene specific to cont rol gene expression 
levels.    
8.3.2 Research Blood  
 
Blood samples for methylation analysis will be collected from a ll participants into the 
enclosed purple top tubes (10 mL EDTA BD Vacutainer cell prepar ation tubes, Becton 
Dickinson, Franklin Lakes, NJ).  T hese tubes are designed to se parate plasma and 
mononuclear cells from whole  blood.  For each collection day, t otal of 50 mL of blood 
will be drawn from the patient (5 tubes of 10 mL each).  Each p urple tube holds 
approximately 10 of blood, yielding close to 5ml of plasma.   
 
 Blood tubes must be kept in ice, a nd processed within 30 minute s of collection. If 
collected at the Johns Hopkins Hos pital, the blood samples will  be processed in Dr. 
Ahuja’s laboratory. For other participating sites, blood must b e kept on ice, processed 
within 30 minutes, and the plasmas and WBC collected must be st ored at or below -70C 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
44 until they can be shipped to Dr. A huja’s laboratory. Overnight express shipping and use 
of adequate amount of dry ice wi ll be practiced to preserve the  quality of specimen in the 
shipping process. All collected s pecimens will be stored at or below -70C in Dr. Ahuja’s 
laboratory. 
Processing of Blood: (For Plasma and White blood cells) 
1. Take 1 empty 15 mL conical tube for  each K2-EDTA tube collected  
2. First add 3 mL of Ficoll-Paque PLUS buffer to each conical tube .  
(NOTE:  Ficoll-Paque PLUS buffer MUST BE KEPT AT 4ºC and out of  l i g h t  f o r  
storage.) 
3. Using one conical tube for each purple top blood tube, Carefull y layer the blood on to Ficoll-
Paque PLUS buffer conical tubes by tilting the conical tube at an angle close to horizontal and 
letting the blood from the purpl e-top tube run very slowly down  the side of the conical tube.  
THIS IS IMPORTANT.  If done correctly, the blood should sit right on top of the bu ffer as 
shown below (Figure A) .  Repeat this step for  each of the tubes.  
4. Next, centrifuge tubes for 10 minutes at 3000 rpm at 4ºC. Be su re that the centrifuge is 
balanced. The layers will now separate as shown below (Figure B).  
5. Carefully pipet the plasma layer (the clear yellow layer on top ) from each conical tube into a 
new 15 mL conical tube (1 tube for each).   
P a y  c a r e f u l  a t t e n t i o n  t o  n o t  d r a w  f r o m  t h e  w h i t e  b u f f y  c o a t  ( t h e second layer below 
plasma in Figure B).  To ensure this, stop pipetting plasma at a level 3.5 mL above t he RBC 
layer (Red layer at the bottom). For example, if the top of the  RBC is at 3mL, then pipet plasma 
out down to 6.5 mL and stop. 
6. Pipet the buffy coat (WBCs) from each conical tube pooling them  into a single new 15 mL 
conical tube.   NOTE:  Gently navigate your pipette tip  to collect clumps of WBC arou nd the buffy coat.  Be 
careful not to draw the Ficoll-Bu ffer sitting below the white b uffy coat (the third layer). 
7. Once plasma and the white buffy coats are collected from each c onical tube you should have, 
depending on the patient sample,  5 conical tubes filled with 4 -5 mL plasma each and one, 
conical tube filled with 2-4 mL WBCs.  You may now discard the conical tubes filled with 
ficoll and RBCs.   
8. Take the single conical tube filled with WBCs and add an equal volume of 1x PBS to the 
volume of WBCs present, mix by inverting 5 times. 
9. Take the single tube with pooled WBCs from step 11 and the 5 tu bes with plasma from step 8. 
Spin all five sample tubes in the centrifuge for 5 minutes at 1 500 rpm at 4ºC. Be sure that the 
centrifuge is balanced. 
10. After centrifugation you may have a small white pellet at the b ottom of each of the plasma 
tubes (5 tubes) and you will have a larger white pellet in the single WBC tube.   
Be careful not to  disturb the pellets in the plasm a tubes or the WBC tubes (Altho ugh you 
will not be collecting the pellets from the 4 tubes with plasma  you do not want them to 
contaminate the plasma)  
11. Take the plasma from the 5 conical plasma tubes.  Into 6 Eppend orf (1.5 mL) tubes Add 0.5 
mL plasma. 
Do not disturb any pellet that may have formed.    
12. Add the remaining plasma in 1.0 mL aliquots into additional 1.5  mL Eppendorf tubes (between 
12 and 16 tubes).   
Do not disturb any pellet that may have formed.    
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
45 13. Now take the conical tube with the WBCs.  There should be a whi te pellet at the bottom You 
want this pellet.     
14. Being careful not to disturb the pellet  Remove by pipetting (Do not decant) and discard any 
liquid from the conical tube (leave a little liquid ~200 uL b ehind to make sure the pellet i s 
not disturbed) .   
15. Add 3 mL 1x PBS to the pellet and mix by flicking the tube gent ly to re-suspend the cells.    
(If the cells do not re-suspend by flicking the tube you may ca refully pipet the cells up 
and down to re-suspend them in the PBS)  
16. Once the cells have been re-suspended add 6 aliquots of 0.5 mL of the WBCs in step 18 into 
1.5 mL Eppendorf tubes.   
17. When finished you should have 6 tubes with 0.5 mL of plasma fro m step 14; 16-20 tubes with 
1.0 mL of plasma from step 15; a nd 6 tubes with 0.5 mL of WBCs from step 19.  
18. Label samples as PLASMA  OR WBC , as applicable, including study number (J1369), unique 
patient ID (assigned by the consor tium), date of collection, an d time point in treatment cycle. 
19. Freeze plasma and WBC samples in their Eppendorf tubes at or be low -70ºC until shipment or 
transfer to Dr. Nita Ahuja’s Laboratory. 
 
 
 
 
CRITICAL POINT:  At time of shipping, fill an insulated styrofoam box 
with DRY ICE  (NOT ICE ), enough to fill at least ¾ of the box. This will 
ensure that plenty of dry ice remains during the duration of th e delivery 
process to protect the quality of the specimens.  Fill half the  box with 
DRY ICE, place the specimens in the middle, and fill up to top with DRY 
ICE. 
 
Figure B: 
 Figure A : 

J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
46 a. Shipping of processed Plasma/ WBC can be bundled and sent at 
the end of the trial. They must be  sent via overnight express. Please 
avoid shipping out on Fridays to p revent arrival of items over the 
weekend. b.  Shipping of the biopsies may be  sent to Dr. Nita Ahuja’s 
laboratory as a batched collecti on as long as they  were prepare d and 
stored according to the instructions outlined above (must be stored 
at or below -70C until shipment).   To avoid weekend arrivals, 
biopsies must not be shippe d out on a Thursday or Friday.   
 
All tubes must be clearly label ed with the unique patient ID (a ssigned by the consortium), 
Cycle and Day, specimen type (Plas ma, WBC, or bi opsy) and Date of collection.  
 
During the course of the study, bl ood and tumor biopsies will b e shipped from the centers 
to the coordinating center lab a t Johns Hopkins University Scho ol of Medicine.  After 
conclusion of the study, samples will be sent for analysis to D r. Nita Ahuja’s laboratory 
at the Yale School of Medicine.   
 
  
 
   
9  STUDY CALENDARS 
 
Baseline evaluations are to be conducted within 2-week prior to  start of protocol 
therapy. Scans must be done <4 weeks prior to the start of ther apy. In the event that the 
participant's conditi on is deteriorating, la boratory evaluation s should be re peated within 
48 hours prior t o initiation of the nex t cycle of therapy 
All assessments must b e performed pr ior to administration of an y study 
medication. All stu dy assessments and medic ations should be adm inistered within 
+ 3 days of the protocol-specified  date, unless ot herwise noted .  
  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
47 Phase I Portion – Dose levels -1G, -1, 1, 1G, and 2 
 
 
 Pre- 
Study C1  
d1 C1   
d8 C1 
d9-14 C1 
d15 C1 
d22 C2 
d1 C2 
d8   C2    
d15 C2 
d22 C3 
d1a C3 d8
 a C3 
d15 a C3 
d22 a Off  
Studyc  
SGI-110 Days 1-5  X      X     X      
Irinotecan   X  X   X X   X X   
Growth Factor Support     
Xf            
Informed consent X               
History X               
Concurrent meds X X X  X X X X X  X X X  X 
Physical exam (Ht, Wt, 
BSA, VS)e X X   
  X     X     X  
Performance Status X X     X     X     X 
CBC w/diff, plts X X X  X X X X X  X X X  X 
Serum chemistryb X X X  X X X X X  X X X  X 
CEA X X     X     X     X 
Urinalysis X X     X     X     X 
ECG X               
Adverse event evaluation   
X-------------------------------------------------------------- ----------------------------------------------------X X 
 
Tumor measurements  
X  
Repeated every 8 weeks. Documenta tion (radiologic) must be prov ided for subjects 
removed from study for progressive disease. Xc 
Radiologic evaluation X  Radiologic measurements should  be performed every 8 weeks Xc 
B-HCG  
Xd               
Tumor biopsy X  X             
Archival Tissue X               
Research Bloods  X  X   X X X X X  X    X 
PK Study  X               
 a: All study calendar evaluations for cycle 3 are representati ve of cycle 3 and beyond. 
b: Albumin, alkaline phosphatase , total bilirubin, BUN, calcium , chloride, glucose, phosphorus, potassium, total  protein, SGO T   
[AST], SGPT [ALT], sodium. 
c: Off-study evaluation should be  performed within 30 days of l ast dose. 
d: Serum pregnancy test (women of childbearing potential). 
e: Baseline height will be meas ured and recorded once during pr e-study, and this value for he ight will be used through the pat ient’s 
duration of study.  
f: Growth factor support will be initiated with filgrastim 5mcg /kg/day on cycle 1 day 9-14 for patients enrolled on Dose level s -1G 
and 1G. Additional growth facto r support during Cycle 1 and on subsequent cycles will be provi ded per clinician judgment.  
  
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
48 Phase I Portion – Dose level 3 
 
 Pre- 
Study C1  
d1 C1   
d8 C1 
d9-14 C1 
d15C1 
d22 C2 
d1 C2 d8   C2     
d15 C2 
d22 C3 
d1a C3 d8
 a C3 
d15 a C3 
d22 a Off  
Studyc 
SGI-110 Days 1-5  X      X     X      
Irinotecan  X X  X  X X X  X X X   
Informed consent X               
History X               
Concurrent meds X X X  X X X X X  X X X  X 
Physical exam (Ht, Wt, 
BSA, VS)e X X   
  X     X     X  
Performance Status X X     X     X     X 
CBC w/diff, plts X X X  X X X X X  X X X  X 
Serum chemistryb X X X  X X X X X  X X X  X 
CEA X X     X     X     X 
Urinalysis X X     X     X     X 
ECG X               
Adverse event evaluation   
X-------------------------------------------------------------- -------------------------------------------------X X 
 
Tumor measurements  
X  
Repeated every 8 weeks. Documenta tion (radiologic) must be prov ided for subjects 
removed from study for progressive disease. Xc 
Radiologic evaluation X  Radiologic measurements should  be performed every 8 weeks Xc 
B-HCG  
Xd               
Tumor biopsy X  X             
Archival Tissue X               
Research Bloods  X  X   X X X X X  X    X 
PK Study  X               
  
a: All study calendar evaluations for cycle 3 are representativ e of cycle 3 and beyond. 
b: Albumin, alkaline phosphatase , total bilirubin, BUN, calcium , chloride, glucose, phosphorus, potassium, total  protein, SGO T   
[AST], SGPT [ALT], sodium. 
c: Off-study evaluation should be  performed within 30 days of l ast dose. 
d: Serum pregnancy test (women of childbearing potential). 
e: Baseline height will be measur ed and recorded once pre-study , and this value for height will  be used through the patient’s duration
of study.  
  
 
    
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
49 Phase II Portion 
Arm A – SGI-110 + Irinotecan 
 
 
 Pre- 
Stud
yC1  d1 C1   
d8 C1 
d9-
14C1 
d15 C1 
d22 C2 
d1 C2 
d8   C2    
d15 C2 
d22 C3 
d1b C3 
d8 b C3 
d15 b C3 
d22 b Off  
Studyc  
SGI-110 Days 1-5a  X      X     X      
Irinotecana   X  X   X X   X X   
Growth factor support    X--- a           
Informed consent X               
History X               
QoL questionnaire  X          Xi    X  
Concurrent meds X X X  X X X X X  X X X  X 
Physical exam (Ht, Wt, 
BSA, VS)g X X     X    X    X 
Performance Status X X     X    X    X 
CBC w/diff, plts X X X  X X X X X  X X X  X 
Serum chemistryd X X X  X X X X X  X X X  X 
CEA X X     X    X    X 
Urinalysis X X     X    X    X 
ECG X               
Adverse event evaluation   X-------------------------------------------------------------- ----------------------------------------
-------XX 
 
Tumor measurements  
X  Repeated every 8 weeks. Documenta tion (radiologic) must be prov ided for subjects 
removed from study for progressive disease. Xe 
Radiologic evaluation X  Radiologic measurements should be perf ormed every 8 weeks Xe 
Archival Tissue X    
B-HCG  
Xf               
Tumor Biopsy Xh        
Xh -------Xh       
Research Bloods  X X  X X X X X  X  X  X 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
50  
   a: Arm A -Dose Level 1G from Phase I, SGI-110 45mg/m2 D1-5, Ir inotecan 125mg/m2 D8 and 15. Tr eatment cycle is 28 days. Growth  factor support of 
filgrastim (or institutional equi valent) 5mcg/kg/day on days 9- 14 and peg-filgrastim 6mg on day 16 of cycle 1 is mandatory. Ad ditional growth factor 
support during Cycle 1 and on subsequent cycles will be provide d per clinician judgment. 
b: All study calendar evaluations for cycle 3 are representativ e of cycle 3 and beyond. 
c: Off-study evaluation should be  performed within 30 days of l ast dose. 
d: Albumin, alkaline phosphatas e, total bilirubin, BUN, calcium , chloride, glucose, phosphorus, potassium, total  protein, SGO T   [AST], SGPT [ALT], 
sodium. 
f: Serum pregnancy test (women of childbearing potential). g: B aseline height will be measured and recorded once pre-study, an d this value for height 
will be used through the patie nt’s duration of study 
h: SKCCC, VUMC, MSKCCC, and USC-Norris, will obtain biopsies on  a total of 36 patients (distributed roughly evenly between the  sites) for the first 
patients enrolled to the phase 2 if they have both biopsiable di sease and are randomized to SG I-110 + Irinotecan.  Additional o ptional biopsy will be 
requested of patients with baselin e research biopsy who remain on trial through Cycle 6-9. 
i: QoL surveys will be done on C3D1 and every other cycle subse quently (i.e. Cycle 5 Day 1, Cycle 7 Day 1, etc) 
 
  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
51 Arm B - Regorafenib 
 
   
 
 Pre- 
Study C1  d1 C1   
d8 C1 
d15 C1 
d22 C2 
d1 C2 
d8   C2    
d15 C2 
d22 C3 
d1aC3 d8
  a C3 
d15  a C3 
d22  a Off  
Studyb  
Regorafenibc  X  - - - - - - - - - - - 
-  X  - - - - - - - - - - - 
- X  - - - - - - - - - - - -   
Informed consent X              
History X              
QoL questionnaire  X        Xd    X  
Concurrent meds X X  X  X  X  X    X 
Physical exam (Ht, Wt, 
BSA, VS)e X X    X    X    X 
Performance Status X X    X    X    X 
Blood Pressuref  X X X X X X        
CBC w/diff, plts X X  X  X  X  X    X 
Serum chemistryg X X  X  X  X  X    X 
Lipase  X             
CEA X X    X    X    X 
Urinalysis X             X 
ECG X              
Adverse event 
evaluation  X------------------------------------------------------------- ---------------------------------------X X 
 
Tumor measurements  
X Repeated every 8 weeks. Documenta tion (radiologic) must be prov ided for subjects 
removed from study for progressive disease. Xb 
Radiologic evaluation X Radiologic measurements should be perfo rmed every 8 weeks Xb 
Archival Tissue X   
B-HCG  
Xh              
Research Bloods  X  X  X  X  X    X 
a: All study calendar evaluations for cycle 3 are representativ e of cycle 3 and beyond. 
b: Off-study evaluation should be  performed within 30 days of l ast dose. 
c: Arm B (regorafenib 160 mg/day days 1-21). Treatment cycle is  28 days 
d: QoL surveys will be done on C3 D1 and every other cycle subse quently (i.e. Cycle 5 Day 1, Cycle 7 Day 1, etc) 
e: Baseline height will be measur ed and recorded once pre-study , and this value for height will be used through the patient’s duration of study 
f: Weekly blood pressures for first 6 weeks (can be checked wit h primary care physician or at patient’s home), further blood p ressure monitoring as 
determined by history of abnormality 
g: Albumin, alkaline phosphatas e, total bilirubin, BUN, calcium , chloride, glucose, phosphorus, potassium, total  protein, SGO T   [AST], SGPT [ALT], 
sodium. 
h: Serum pregnancy test (women of childbearing potential). 
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
52 Arm B – TAS-102 
 
 
 
 Pre- 
StudC1  d1 C1   
d8 C1 
d15 C1 
d22 C2 
d1 C2 
d8   C2    
d15 C2 
d22 C3 
d1aC3 d8
  a C3 
d15  a C3 
d22  a Off  
Studyb  
TAS-102c  X-------------   X-------------   X-------------    
Informed consent X               
History X               
QoL questionnaire  X         Xd    X  
Concurrent meds X X  X  X  X  X    X 
Physical exam (Ht, Wt, 
BSA, VS)e X X    X    X    X 
Performance Status X X    X    X    X 
CBC w/diff, plts X X  X  X  X  X    X 
Serum chemistryf X X  X  X  X  X    X 
CEA X X    X    X    X 
Urinalysis X             X 
ECG X              
Adverse event evaluation  X------------------------------------------------------------- ---------------------------------------X X 
 
Tumor measurements  
X Repeated every 8 weeks. Documenta tion (radiologic) must be prov ided for subjects 
removed from study for progressive disease. Xb 
Radiologic evaluation X Radiologic measurements should be perfo rmed every 8 weeks Xb 
Archival Tissue X   
B-HCG  
Xg              
Research Bloods  X  X  X  X  X    X 
a: All study calendar evaluations for cycle 3 are representativ e of cycle 3 and beyond. 
b: Off-study evaluation should be  performed within 30 days of l ast dose. 
c: Arm B (TAS-102 35mg/m2 twice a day on Days 1-5 and 8-12). Tr eatment cycle is 28 days 
d: QoL surveys will be done on C3 D1 and every other cycle subse quently (i.e. Cycle 5 Day 1, Cycle 7 Day 1, etc) 
e: Baseline height will be measur ed and recorded once pre-study , and this value for height will be used through the patient’s duration of study 
f: Albumin, alkaline phosphatase , total bilirubin, BUN, calcium , chloride, glucose, phosphorus, potassium, total  protein, SGO T   [AST], SGPT [ALT], 
sodium. g: Serum pregnancy test (women of childbearing potential). 
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
53 10 MEASUREMENT OF EFFECT   
 
As epigenetic agents may take ma ny months to show their benefit  a s  s e e n  i n  M D S / A M L  
studies,25 in both Phase 1 and Phase 2, subjects receiving SGI-110 + irin otecan may continue 
receiving their assigned treatment if their disease progresses based on RECIST 1.1 criteria if 1) 
the patient is clinically stable, 2) the patient is informed of  their scan results and agrees to  
continue therapy, and 3) the patient’s provider agrees that rem aining on study would be 
appropriate for the patient.39  
 
Although response is not the prim ary endpoint of this trial, pa rticipants with measurable 
and/or non-measurable disease w ill be assessed by RECIST 1.1 cr iteria.39 For the 
purposes of this study, particip ants should be reevaluated appr oximately every 8 weeks. 
In addition to a baseline scan, co nfirmatory scans should also be obtained at least 4 
weeks following initial documen tation of an objective response.  
10.1 Antitumor Effect– Solid Tumors 
For the purposes of this study, pa rticipants should be re-evalu ated for response every 8 
weeks. In addition to a baseline scan, confirmatory scans shoul d also be obtained not less 
than 4 weeks following initial doc umentation of objective respo nse. 
Response and progression will be evaluated in this study using the new international 
criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 
guideline .39 Changes in the diameter (unidimensional measurement) of the tum or 
lesions are used in the RECIST criteria. 
10.1.1  Definitions  
Evaluable for toxicity. All participants who receive at least o ne dose of study 
treatment will be evaluable for toxicity from the time of their  first treatment.  
Evaluable for objective respons e. Only those participants who h ave 
measurable disease present at ba seline, have rece ived at least one cycle of 
therapy, and have had their disease re-evaluated will be consid ered evaluable 
for response. These participants will have their response classified according 
to the definitions stated below. (Note: Participants who exhibi t objective 
disease progression or die pri or to the end of cycle 1 will als o be considered 
evaluable). 
10.1.2  Disease Parameters 
Measurable disease. Measurable disease is the presence of at le ast one 
(1) lesion that can be accurately measured in at least one dimension with 
longest diameter  >20 millimeters (mm) using conventional techniques (CT, 
MRI, x-ray) or  >10 mm with spira l CT scan. Measurable lesions must be at 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
54 least 2 times the slice thickness in mm. All tumor measurements  must be 
recorded in millimeters (or decimal fractions of centimeters). 
Reminder:  A lesion in a previously irradia ted area is not eligible for 
measurable disease unle ss there is objective evidence of progre ssion of the 
lesion prior to study enrollment. Lesions in  previously irradia ted areas 
must be clearly identified as such. 
  
Malignant lymph nodes. To be considered pathologically enlarged  and 
measurable, a lymph node must b e > 15 mm in short axis when ass essed by CT 
scan (CT scan slice thickness re commended to be no greater than  5 mm). At 
baseline and in follow-up, only th e short axis will be measured  and followed. 
 Non-measurab le disease.  
 
All other lesions (or sites of d isease), including small lesion s (longest diameter 
<10 mm or pathological lymph nodes with > 10 to < 15mm short ax is, are 
considered non-measurable disease. Bone lesions, leptomeningeal  disease, 
ascites, pleural/pericardial effusions, lymphangitis cutis/pulm onis, inflammatory 
breast disease, abdominal masses identified by physical exam th at are not 
measurable by reproducible imagi ng techniques, and cystic lesio ns are all 
considered non-measurable. 
Target lesions.  
All measurable lesions up to a ma ximum of 2 lesions per organ a nd 5 lesions 
in total, representative of all involved organs, should be iden tified as target 
lesions and recorded and measured at baseline. Lesions must be accurately 
measured in 1 dimension with a min imum size of 10 mm by CT or M RI (slice 
thickness no greater t han 5 mm), 20 mm by chest  x-ray. Nodes must have a 
short axis > 15 mm. The short axis should be included in the su m of the 
lesions in the calculation of res ponse. Nodes that shrink to < 10 mm are 
considered normal. Target lesi ons should be selected on the bas is of their size, 
be representative of all the involved organs, and should be les ions that can be 
followed with reproducible repeated measurements.  
Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue 
components , that can be evaluated by cross sectional imaging techniques s uch as 
CT or MRI can be considere d target lesions if the soft tissue component  meets 
the definition of measurability a s defined above. Cystic lesion s thought to 
represent cystic metastases ca n be considered as target lesions . However, if non-
cystic lesions are present, the se are preferre d for selection a s target lesions. 
Lesions in previously irradiate d areas or areas subject to othe r loco-regional 
therapy are usually no t considered measurab le unless there has been 
demonstrated progression of that lesion.  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
55 Non-target lesions.  
All other lesions, including small lesions < 10 mm or pathologi cal lymph 
nodes measuring > 10 mm to < 15 mm  in short axis, as well as tr uly non-
measurable lesions, which include leptomeningeal disease, ascit es, pleural or 
pericardial effusion, inflammato ry breast disease, lymphangitic  involvement of 
skin or lung, abdominal masses identified by physical exam that  are not 
measurable by reproducible imaging techniques.  
10.1.3  Methods for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notatio n, using a ruler, 
calipers, or digital measurement tool. All baseline evaluations  should be performed 
as closely as possible to the beginning of treatment and never more than 4 weeks 
before the beginning of the treatment. 
The same method of assessment and the same technique should be used to 
characterize each identified and reported lesion at baseline an d during follow-up. 
Imaging-based evaluation is pr eferred to evalu ation by clinical  examination 
when both methods have been used to a ssess the anti-tumor effec t of a 
treatment. 
Clinical lesions. Clinical les ions will only be considered meas urable when they are 
superficial (e.g., skin nodules a nd palpable lymph nodes). For the case of 
skin lesions, documentation by c olor photography, i ncluding a r uler to estimate 
the size of the lesion, is recommended. 
Chest x-ray. Lesions on chest x -ray are acceptable as measurabl e lesions when 
they are clearly defined and surrounded by aerated lung; howeve r, CT is 
preferable. 
Conventional CT and MRI. These t echniques should be performed w ith cuts of 
10 mm or less in slice thickness contiguously. Spiral CT should  be performed 
using a 5 mm contiguous reconstruction algor ithm. This applies to tumors of the 
chest, abdomen, and pelvis. Head and neck tumors and those of extremities 
usually require specific protocols. 
Ultrasound (US). When the primary endpoint of the study is objective 
response evaluation, US should not be used to measure tumor lesions. It is, 
however, a possible alternative to clinical  measurements of superficial palpable 
lymph nodes, subcutaneous lesions, and thyroid nodules. US might also be useful 
to confirm the complete disappearance of superficial lesions usually 
assessed by clinical examination. 
FDG PET and PET/CT. FDG PET will not be used f or response assessment  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
56 Endoscopy, Laparoscopy. The utilization of these techniques for objective 
tumor evaluation has  not yet been fully and widely validated. Their uses in this 
specific context require sophisticated e quipment and a high level of expertise 
that may only be available in some centers. Therefore, the utilization of such 
techniques for objective tumor response should be restricted to validation 
purposes in reference centers. However, such techniques may be useful to 
confirm complete pathological response when biopsies are obtained . 
Tumor markers. Tumor marke rs alone cannot be used to assess response. If 
markers are initially above the upper normal limit, they must normalize for 
a subject to be considered in complete clinical response.  
10.1.4  Response Criteria  
10.1.4.1  Evaluation of Target Lesions 
 Complete Response (CR):  
Disappearance of all target lesi ons. Any pathological lymph nod e must 
have reduction in short axis to < 10 mm. 
Partial Response (PR):  
At least a 30% decreas e in the sum of the diameters of target lesions, 
taking as reference the base line sum diameters. 
 Progressive Disease (PD):  
 At least a 20% increase in the  sum of the diameters of target lesions, 
taking as reference the smallest sum  on study with at  least a 5 
mm absolute increase in the  sum of all lesions. The 
appearance of one or more new  lesions* denotes disease 
progression.  
 Stable Disease (SD):  
 Neither sufficient shrinkage to  qualify for PR nor sufficient increase 
to qualify for PD, taking as reference the smallest sum diamete rs 
while on study. 
Unknown (UN): Assessment of targe t lesions cannot be made due t o 
insufficient or uneval uable data. In this case, a concise expla nation must 
be given. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
57 Note : If tumor response data is mi ssing for target lesions, the ove rall 
assessment must be UN  unless there is new d isease that would re sult in 
an overall assessment of PD. H owever, if there is missing or 
unevaluable data for non-target lesions, but data is available for all 
target lesions, the overall resp onse for that time point will b e assigned 
based on the sum LD of all targe t lesions. Additionally, the as sessment 
of CR cannot be made if there is missing or unevaluable data fo r non-
target lesions. In this case, t he overall assessm ent would be P R. 
*Definition of New Lesion : The finding of a new lesi on should be unequivocal 
(i.e. not due to diffe rence in scanning tec hnique, imaging moda lity, or findings 
thought to represent something oth er than tumor (ex: new bone l esions may be 
healing or flare of pre- existing lesions). H owever, a lesion id entified on a 
follow-up scan in an anatomical l ocation that was not scanned a t baseline is 
considered new and will indicate  PD. If a new lesion is equivoc al (because of 
small size, etc.), follow-up evalu ation will clarify if it trul y represents new 
disease and if PD is  confirmed, progressio n should be declared using the date of 
the initial scan on w hich the lesion was discovered.  
10.1.4.2  Evaluation of Non-Target Lesions 
 Complete Response (CR): Disa ppearance of all non-target lesion s and 
normalization of tumor marker leve l. All lymph nodes must be no n-
pathological in size ( < 10 mm short axis).  
Note:  If tumor markers are initially above the upper normal limit, 
they must normalize for a subj ect to be considered in complete 
clinical response. 
Incomplete Response/St able Disease (SD): Persistence of one or 
more non-target lesions and/or maintenance of tumor marker leve l 
above the normal limits. 
Progressive Disease (PD): Appearance of one or more new 
lesions* (new lesions must be > slice thickness) and/or 
unequivocal progression of exi sting non-target lesions. 
Overall level of substantial wors ening that merits discontinuat ion 
of therapy. A useful test that can be applied when assessing no n-
targets for unequivocal progressi on is to consider if the incre ase 
in overall disease burden base d on the change in non-measurable  
disease is comparable in magnitu de to the increase that would b e 
required to declare PD for measurable disease.  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
58 Unknown (UN): Assessment of non-targ et lesions cannot be made d ue 
to insufficient or unevaluable  data. In this case , a concise ex planation 
must be given. 
10.1.4.3  Evaluation of Best Overall Response 
The best overall response is the b est response recorded from th e start of 
the treatment until disease progression/recurrence (taking as r eference 
for progressive disease the sma llest measurements recorded sinc e the 
treatment started). The participant's best response assignment will 
depend on the achievement of  both measurement and confirmation 
criteria. 
For Patients with Measurable Disease (i.e., Target Disease)  
 
Target 
Lesions Non-Target 
Lesions New 
Lesions Overall 
Response Best Overall Response for 
when Confirmation is 
Required: 
CR CR No CR >4 wks confirmation 
CR 
Non-CR/Non-PDNo PR 
>4 wks confirmation CR Not evaluate d NoP R
PR Non-CR/Non-
PD/Not 
evaluated No PR 
SD Non-CR/Non-
PD/Not 
evaluate dNo SD Documented at least once 
>4 wks from baseline 
PD An y Yes or No PD No prior SD, PR or CR 
Any P D * Yes or No PD
Any A n y Yes PD
* In exceptional circumstances, unequivocal progression in non-target lesions may be 
accepted as disease progression. 
 
Note:   Participants with a global deterioration of health status requiring discontinuation of 
treatment without objective evidence of disease progression at that time should be 
reported as "symptomatic deterioration". Every effort should be made to document the 
objective progression even after discontinuation of treatment. 
 
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
59 For Patients with Non-Measurabl e Disease (i.e., Non-Target Dise ase) 
 
Non-Target Lesions New 
Lesions Overall Response 
CR No CR 
Non-CR/non-PD No NonCR/non-PD 
Not all evaluated No Not evaluated 
Unequivocal PD Yes or No PD 
Any Yes PD 
Non-CR/non-PD is preferred over stable disease for non-target d isease since SD is 
increasingly used an endpoint fo r assessment of efficacy in som e trials so to assign this 
category when no lesions can be measured is not advised.  
10.1.5  Duration of Response 
Duration of overall response: The  duration of overall response is measured from 
the time measurement criteria are  met for CR or PR (whichever i s first recorded) 
until the first date that recurrence or PD is objectively docum ented, taking as 
reference for PD the smallest measurements recorded since the t reatment started. 
Duration of overall complete response: The duration of overall CR is 
measured from the time measuremen t criteria are first met for C R until the 
first date that recurrent disease is objectively documented. 
Duration of stable disease: Stabl e disease is measured from the  start of the 
treatment until the criteria f or progression are met, taking as  reference the 
smallest measurements recorded s ince the treatment started. 
10.1.6  Progression-Free Survival 
Progression-Free Survival (PFS) is defined as the duration of t ime from start of 
treatment to tim e to progression event, including objective dis ease progression, 
clinical deterioration attr ibuted to disease, or death. 
10.2 Other Response Parameters 
 
CEA will be followe d on study monthly for e xploratory  purposes but will not be used for 
response assessment.  Additionally in the ph ase II portion of the  study, all subjects  will be asked to complete a 
quality of life assessm ent using the Functional Assessment of C ancer Therapy (FACT-C) 
questionnaire at the start of s tudy Cycle 1 Day  1, Cycle 3 Day 1, every other cycle 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
60 subsequently (i.e. Cyc le 5 Day 1, Cycle 7 D ay 1, etc), and at e nd of study/study withdrawal 
(optional).  
11 ADVERSE EVENT REPORTING REQUIREMENTS 
 
11.1 Definitions 
11.1.1  Adverse Event (AE)  
 
An adverse event (AE) is any unde sirable sign, symptom or medic al condition or 
experience that develops or worse ns in severity after starting the first dose of 
study treatment or any procedure sp ecified in the protocol, eve n if the event is not 
considered to be related to the study.  
 
Abnormal laboratory values or diag nostic test results constitut e adverse events 
only if they induce clinical signs  or symptoms or require treat ment or further 
diagnostic tests.    
11.1.2  Serious adverse event (SAE)  
 A serious adverse event (SAE) i s any adverse event, occurring a t any dose and 
regardless of causality that:  
 Results in death 
 Is life-threatening. Life-threat ening means that the person was  at 
immediate risk of death from th e reaction as it occurred, i.e.,  it does not 
include a reaction which hypothe tically might have caused death  had it 
occurred in a more severe form. 
 Requires or prolongs inpatient  hospitalization (i.e., the event  required at 
least a 24-hour hospitalizati on or prolonged a hospitalization beyond the 
expected length of stay). Hosp italization admissions and/or sur gical 
operations scheduled to occur  during the study period, but plan ned prior to 
study entry are not considered SAE s if the illness or disease e xisted before 
the person was enrolled in the t rial, provided that it did not deteriorate in 
an unexpected manner during the t rial (e.g., surgery performed earlier than 
planned). 
 Results in persistent or signifi cant disability /incapacity. Dis ability is 
defined as a substantial disr uption of a person’s ability to co nduct normal 
life functions. 
 Is a congenital anomaly or birth defect; or 
 Is an important medical event  when, based upon appropriate medi
cal 
judgment, it may jeopardize the participant and require medical  or surgical 
intervention to prevent one of  the outcomes listed above. Examp les of 
such medical events include all ergic bronchospasm requiring int ensive 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
61 treatment in an emergency room or  at home; blood dyscrasias or 
convulsions that do not result i n inpatient hospitalization, or  the 
development of drug dependency or drug abuse. 
 
Events not considered to be serious advers e events are hosp italizations fo r: 
 routine treatment or monitoring of  the studied indication, not associated 
with any deterioration in conditi on, or for elective procedures  
 elective or pre-planned treatme nt for a pre-existing condition that did not 
worsen 
 emergency outpatient treatment for an event not fulfilling the serious 
criteria outlined above and not res ulting in inpatient admissio n 
 respite care 
  
11.1.3  Expectedness 
 
Adverse events can be 'Exp ected' or 'Unexpected.'  
11.1.3.1  Expected adverse event  
 
Expected adverse events are t hose that have been  previously ide ntified as 
resulting from administration of  the agent. For the purposes of  this study, 
an adverse event is considered e xpected when it appears in the current 
adverse event list, the Investig ator’s Brochure, the package in sert or is 
included in the informed consen t document as a potential risk.    
 
Refer to Section 6 for a listing  of expected adverse events ass ociated 
with the study agent(s). 
11.1.3.2  Unexpected adverse event  
  
For the purposes of this study, an a dverse event is considered unexpected 
when it varies in nature, intens ity or frequency from informati on 
provided in the current adverse event list, the Investigator’s Brochure, 
the package insert or when it is  not included in the informed c onsent 
document as a potential risk.   
11.1.4  Attribution 
 Attribution is the r elationship between an adverse event or ser ious adverse event 
and the study treatment. Attribution will be assigned as follow s:  
 
 Related – There is reasonable evi dence that the AE is related  to the study 
treatment. 
 Unrelated - The AE i s clearly NOT related  to the study treatment. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
62 11.2 Procedures for AE and SAE Recording and Reporting 
 
Participating investigators will assess the occurrence of AEs a nd SAEs at all participant 
evaluation time points during the study.   All AEs and SAEs whether report ed by the participant, discovere d during questioning, 
directly observed, or detected by phy sical examination, laborat ory test or other means, 
will be recorded in the partici pant’s medical record and on the  appropriate study-
specific case report forms.   The descriptions and grading sca les found in the revised NCI Co mmon Terminology 
Criteria for Adverse Events (CTCAE) version 4.0 will be utilize d for AE reporting. All 
appropriate treatment areas should have access to a copy of the  CTCAE version 4.0. 
A copy of the CTCAE version 4.0 ca n be downloaded from the CTEP  website at: 
  http://ctep.cancer.gov/protocolDev elopment/electronic_applicati ons/ctc.htm .  
 
11.3 Reporting Requirements 
 
Each participating investigator  is required to abide by the rep orting requirements. The 
study must be conducted in compliance with FDA regulations, loc al safety reporting 
requirements, and reporting require ments of the principal inves tigator.  
 
Each investigative site will be responsible to report SAEs that  occur at that institution 
to their respective IRB. It is the responsibility of each parti cipating investigator to 
report serious adverse events t o the PI of this study, Dr. Azad , and/or others as 
described below.  
11.4 Reporting to the Study Sponsor 
11.4.1  Serious Adverse Event Reporting 
 All serious adverse events that occur after th e initial dose of  study treatment, 
during treatment, or within 30 days o f the last dose of treatme nt must be reported 
to the Principal Investigator , Dr. Azad, on the local instituti onal SAE form. This 
includes events meeting the criteria outlined in Section 11.1.2 , as well as the 
following:  
 Grade 2 (moderate) and Grade 3 ( severe) Events – Only events th at are 
unexpected and related wit h the intervention. 
 
 All Grade 4 (life-threatening or  disabling) Events – Unless exp ected AND 
specifically listed in the protoc ol as not requiring reporting.  
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
63  All Grade 5 (fatal) Events – Whe n the participant is enrolled a nd actively 
participating in the trial OR when the event occurs within 30 d ays of the 
last study intervention.  
 Note: If the participant is i n long term follow up, report the death at the time 
of continuing review.  
 Participating investigators mu st report each serious adverse ev ent to the Principal 
Investigator Dr. Azad withi n 24 hours of learning of the occurr ence. In the event 
that the participating investig ator does not become aware of th e serious adverse 
event immediately (e.g., particip ant sought treatment elsewhere ), the participating 
investigator is to report the event within 24 hours after learn ing of it and 
document the time of his or her first awareness of the adverse event. Report 
serious adverse events by, email to:  
     Email: GISafetyReporting@jhmi.edu 
 
Within the following 24-48 hours, t he participating investigato r must provide 
follow-up information on the serious  adverse event. Follow-up i nformation should 
describe whether the event has resolved or continues, if and ho w the event was 
treated, and whether the participant will continue or discontin ue study 
participation.  Coordinating center will fax or  email serious adverse events (i nitial and follow-up 
reports) to Astex Drug Safety w ithin 24 hours of receiving SAE report to:  
  
Astex Drug Safety  
North America Local Fax:  925.551.3226  
North America Toll-Free Fax:  1.800.576.6568 Email: drugsafety@astx.com  
 Astex Pharmaceuticals will provide a quarterly listing of all S AEs received to 
Sidney Kimmel Comprehensive Can cer Center at Johns Hopkins for comparison 
with the Sponsor’s  listing.  Any missing SAEs or any discrepanc ies will be 
reported at that time. 
11.4.2  Non-Serious Advers e Event Reporting  
 Non-serious adverse events will be reported to the Principal In vestigator Dr. Azad 
on the toxicity Case Report Forms.    
11.5 Reporting to the Institutional Review Board (IRB) 
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
64 Other investigative sites shoul d report serious adverse events to their respective IRB 
according to the local IRB’s policies and procedures in reporti ng adverse events. A 
copy of the submitted institutional SAE form should be forwarde d to: 
 
  Dr. Nilofer Azad       Email: GISafetyreporting@jhmi.edu  
The Principal Investigator Dr. Azad will submit SAE reports fro m outside institutions to 
the SKCCC IRB per their policies and procedures in reporting ad verse events.  
11.6 Reporting to the Food and Drug Administration (FDA) 
 
The Principal Investigator Dr . Azad, as holder of the IND, will  be responsible for all 
communication with the FDA. Dr. Azad will report to the FDA, re gardless of the site of 
occurrence, any adverse event th at is serious, un expected and r elated  to the study 
treatment (Suspected Unexpecte d Serious Adverse Reactions or SU SARs) according 
the regulatory-defined timelin es (7-day or 15-day reports). Dr.  Azad will copy Astex 
pharmaceuticals (SGI-110 manuf acturer) on any such reports. 
   
In accordance with the regulation 21 CFR § 312.33, the IND Spon sor shall within 60 
days of the anniversary date th at the IND went into effect subm it a brief report of the 
adverse events and progress of t he investigation. All IND annua l reports will be 
submitted to the FDA by the IND Sponsor.  Events will be reported to the  FDA using Form FDA 3500A (Mandat ory Reporting 
Form for investigational agents ) or FDA Form 3500 (Voluntary Re porting Form for 
commercial agents). Forms are available at http://www.fda.gov/medwatch/getforms.htm.  
 
7 Calendar-Day Telephone or Fax Report :   
The IND Sponsor is required to notify the FDA of any fatal or l ife-threatening adverse 
event that is unexpected and assessed by the investigator to be  possibly related to the 
investigational agent.  Such reports are to be telephoned or fa xed (301-796-9845) to the 
FDA within 7 calendar days of  first learning of the event.   
 
15 Calendar-Day Written Report :   
The IND Sponsor is required to notify the FDA of any serious ad verse event that is 
unexpected and possibly related to the investigational agent in  a  w r i t t e n  I N D  S a f e t y  
Report.   
 
Written IND Safety Reports should include an Analysis of Simila r Events in accordance 
with regulation 21 CFR § 312.32.  All safety reports previously  filed with the IND 
concerning similar events should be analyzed.  The new report s hould contain comments 
on the significance of the new ev ent in light of the previous, similar reports.  Written IND 
safety reports with Analysis of Similar Events are to be submit ted to the FDA within 15 
calendar days of first l earning of the event.  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
65 11.7 Reporting to Hospital Risk Management 
 
Participating investigators will report to their local Risk Man agement office any subject 
safety reports or sentinel even ts that require reporting accord ing to instituti onal policy. 
11.8 Monitoring of Adverse Events and Period of Observation 
 
All adverse events, both seri ous and non-serious, and deaths th at are encountered from 
initiation of study interventi on, throughout the study, and wit hin 30 days of the last 
study intervention should be follo wed to their resolution, or u ntil the participating 
investigator assesses them as st able, or the participating inve stigator determines the 
event to be irreversib le, or the participan t is lost to follow- up. The presence and 
resolution of AEs and SAEs (with dates) should be documented on  the appropriate case 
report form and recorded in the pa rticipant’s medical record to  facilitate source data 
verification.   For some SAEs, the study sponsor or designee may follow-up by t elephone, fax, and/or 
monitoring visit to obtain additional case details deemed neces sary to appropriately 
evaluate the SAE report (e.g., hos pital discharge summary, cons ultant report, or 
autopsy report).   Participants should be instructe d to report any serious post-st udy event(s) that might 
reasonably be related to partici pation in this study. Participa ting investigators should 
notify the Overall Principal Inve stigator and their respective IRB of any unanticipated 
death or adverse event occurring a fter a participant has discon tinued or terminated 
study participation that may reas onably be related to the study .   
 
12 DATA AND SAFETY MONITORING 
Adverse event lists, guidelines, and instructions for AE report ing can be found in Section 11.0 
(Adverse Events: List an d Reporting Requirements). 
 
12.1 Data Reporting 
 
 12.1.1 This is a Level II stud y under the SKCCC Data Safety Mo nitoring Plan. Data 
monitoring of this protocol will occur on a regular basis with the frequency dependent on the rate 
of subject accrual and the progres s of the study. The protocol will be monitored internally at 
SKCCC by Dr. Nilofer Azad and e xternally by the SKCCC CRO QA Of fice and the 
Coordinating Center in accordance with the JHU SKCCC Data Safet y Monitoring Plan.  Outside 
sites, USC, VUmc, and MSKCCC will use their internal clinical r esearch offices to monitor their 
study patients and regulatory docum ents. Outside sites will pro vide copies of monitoring reports 
to the coordinating center. Eligibility for both sites will be monitored by the SKCCC CRO as 
well.  All trial monitoring and repor ting will be done through the Saf ety Monitoring Committee (SMC) 
at SKCCC.  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
66  
Authorized representatives of th e Coordinating Center may visit  any satellite sites connected to 
the outside sites to perform audits or inspections, including s ource data verification. The purpose 
of these audits or inspections is to systematically and indepen dently examine all trial-related 
activities and documents to determine whether these activities were conducted and data were 
recorded, analyzed, and accurately reported according to the pr otocol, Good Clinical Practice 
(GCP), and any applicable regulatory requirements.   12.1.2 Dr. Azad will be holdin g the IND for this study.  She w ill comply with all 
regulated reporting requirements to the FDA. 
 
13 REGULATORY CONSIDERATIONS 
 
13.1 Protocol Review and Amendments 
This protocol, the proposed infor med consent and all forms of p articipant 
information related to the study  (e.g., advertis ements used to recruit participants) and 
any other necessa ry documents must be sub mitted, reviewed and a pproved by a 
properly constituted IRB gov erning each study location.  
Any changes made to the protocol must be submitted as amendment s and must be 
approved by the IRB pr ior to implementation. Any changes in stu dy conduct must be 
reported to the IRB. The Overall Principal Investigator (or Pro tocol Chair) will 
disseminate protocol amendment info rmation to all p articipating  investigators.  
All decisions of the IRB concerni ng the conduct of the study mu st be made in 
writing. 
13.2 Informed Consent 
 
All participants must  be provided a consen t form describing thi s study and 
providing sufficient in formation for partic ipants to make an in formed decision 
about their particip ation in this s tudy. The formal consent of a participant, using 
the IRB approved conse nt form, must be obt ained before the part icipant is 
involved in any study-r elated procedure. The consent form must be signed and 
dated by the particip ant or the participan t’s legally authorize d representative, and 
by the person obtaining the consent. The participant must be gi ven a copy of the 
signed and dated consent docum ent. The original signed copy of the consent 
document must be retained in the medical record or research fil e.  
13.3 Ethics and Good Clinical Practice (GCP) 
This study is to be conducted a ccording to the fo llowing consid erations, which 
represent good and so und research practice: 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
67  E6 Good Clinical Practic e: Consolidated Guidance 
www.fda.gov/downloads/ RegulatoryInformatio n/Guidances/UCM129515 .pdf  
 US Code of Federal Regulations (CFR) governing clinical study c onduct and 
ethical principles that have thei r origin in the Declaration of  Helsinki 
o Title 21 Part 11 – Electronic Records; E lectronic Signatures 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr11_02.html  
o Title 21 Part 50 – Protection of Human Subjects 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr50_02.html   
o Title 21 Part 54 – Financial Disclosure  by Clinical Investigato rs 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr54_02.html   
o Title 21 Part 5 6 – Institutional Review Boards 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr56_02.html   
o Title 21 Part 3 12 – Investigational  New Drug Application 
www.access.gpo.gov/nara/cfr/wai sidx_02/21cfr312_02.html   
 State laws 
It is understood that deviations  from the protocol should be av oided, except when 
necessary to eliminate an immedi ate hazard to a research partic ipant. In such case, 
the deviation must be reported t o the IRB according to the loca l reporting policy.  
13.4 Study Documentation 
 
The investigator must prepare and maintain adequate and accurat e case histories 
designed to record all observat ions and other data pertinent to  the study for each 
research participant. This info rmation enables the study to be fully documented and the 
study data to be subsequently verified. 
 
Original source documents supporting entries in the case report  forms include but are 
not limited to hospital records, cli nical charts, laboratory an d pharmacy records, 
recorded data from automated ins truments, microfiches, photogra phic negatives, 
microfilm or magnetic m edia, and/or x-rays.  
13.5 Records Retention 
 
All study-related documents must  be retained for  the maximum pe riod required by 
applicable federal regulations and guidelines or institutional policies.  
 
13.6 Data Collection 
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
68 Data will be collected and repor ted on either paper case report  forms (CRF) or through 
an internal data monitoring system, which will be determined pr ior to the start of the 
study. 
13.7 Multi-center Guidelines 
This protocol will adhere to the policies and requirements of t he SKCCC.  
 The Overall Principal Investigator/Coordinating Center is respo nsible for 
distributing all IND Action Lette rs or Safety Reports to all pa rticipating 
institutions for submission to th eir individual IR Bs for action  as required. 
 Mechanisms will be in place to ensure qu ality assura nce, protoc ol compliance, 
and adverse event reporting at each site.  
 Except in very unusual circumstances, each participating instit ution will order 
the agent(s) directly from the supplier. A partic ipating site m ay order the 
agent(s) only after the initial IRB approval for the site has b een forwarded to 
the Coordinating Center.  
 
Multicenter Guidelines  
 
 Protocol Chair (Dr. Azad) 
 The Protocol Chair is responsib le for performing the following  tasks: 
 Coordinating, developing, s ubmitting, and obtaining approval fo r the protocol as well 
as its subsequent amendments. 
 Assuring that all par ticipating institutions  are using the corr ect version of the 
protocol. 
 Taking responsibility for the ove rall conduct of the study at a ll participating 
institutions and for monitoring t he progress of the study. 
 Reviewing and ensuring reporting of  Serious Adverse Events (SAE ) 
 Reviewing data from all sites. 
 
 Coordinating Center 
 The Coordinating Center is respon sible for performing the foll owing tasks: 
 Ensuring that IRB approval has been obtained at each participat ing site prior to the 
first patient registration at t hat site, and maintaining copies  of IRB approvals from 
each site. 
 Managing central patient registration. 
 Collecting and compiling data from each site. 
 Establishing procedures for  documentation, reporting, and submi tting of AE’s and 
SAE’s to the Protocol Chair , and all appli cable parties. 
 Facilitating audits by securing s elected source documents and r esearch records from 
participating sites for audit , or by auditing at participating sites. 
  Participating Sites 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
69  Participating sites are responsible for performing the followi ng tasks: 
 Following the protocol as wr itten, and the guidelines of Good C linical Practice 
(GCP). 
 Submitting data to the Coordinating Center. 
 Registering all patients with t he Coordinating Center by submit ting patient 
registration form, and signed i nformed consent promptly. 
 Providing sufficient experience d clinical and administrative st aff and adequate 
facilities and equipment to conduct a collaborative trial accor ding to the protocol. 
 Maintaining regulatory binde rs on site and providing copies of all required documents 
to the Coordinating Center. 
 Collecting and submitting data according to the schedule specif ied by the protocol.  
 
 
14 STATISTICAL CONSIDERATIONS  
 
The hypothesis of this study is th at SGI-110, a demethylating a gent, can sensitize pretreated 
metastatic colorectal cancer pa tients to retreatment with irino tecan. 
14.1 Study Design/Endpoints 
 
This is a Phase I/II study of Irinotecan and SGI-110 in patient s with locally advanced or metastatic 
colorectal cancer.  The dose escalation portion of the study wi ll be used to determine the preferred 
dose of SGI-110, 30mg/m2, 45 mg/m2 or 60 mg/m2, in combination with Irinotecan.  The second 
portion of this study will be an open-label randomized phase II  study with one arm receiving 
combination SGI-110 plus Irinotecan at the recommended dose fro m phase 1 (determined to be 
SGI-110 45mg/m2, Irinotecan 125mg/m2, with mandatory growth fac tor support) and the other 
arm receiving Regorafenib or TAS-102 at the standard commercial  dose.  The primary objective 
of the study is based on a compa rison of PFS in the SGI-110 arm  to that in the Regorafenib or 
TAS-102 arm, the two approved standard of care drugs in this se tting.  The primary endpoint for 
the Phase II study will be progression free survival (PFS).  Th e study will randomize patients to 
the SGI-110 versus Regorafenib or TAS-102 at a ratio of 2:1.  T he randomized Regorafenib or 
TAS-102 group will provide information about PFS with the stand ard of care drugs to verify 
assumptions made in the design of the study.   Phase I primary objective:  To assess safety and tolerability of Irinotecan in combination with 
SGI-110 in patients with advanced colon cancer. Determine the m aximum tolerated dose (MTD) 
of Irinotecan in combination wit h SGI-110 and recommend a dose for phase II study. 
 
Phase I secondary objectives:    
1. To assess changes in global met hylation and expression at the t umor level with SGI-110 
and Irinotecan treatment.  
2. To assess the pharmacokinetics of SGI-110 in metastatic colon c ancer patients and 
correlate with changes in global methylation.  
 Dose Escalation:  Three dose levels of SGI-110, 30mg/m
2, 45 mg/m2 and 60 mg/m2, will be tested 
in combination with Irinotecan in this portion of the study.  D ose level 1 will be IRI 125 mg/m2 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
70 days 8 and 15 and SGI-110 45 mg/m2 days 1-5 and dose level 2 will be IRI 125 mg/m2 days 8 and 
15 and SGI-110 60 mg/m2 days 1-5; dose level 3 would be SGI-110 at 60 mg/m2 days 1-5 w ith 
IRI at 125 mg/m2 days 1, 8, and 15. Starting with dose level 1,  three patients will be treated in a 
standard 3+3 dose escalation design.  If none of the first thre e patients experiences a DLT then the 
next three will be treated using the next higher dose.  If one o f  t h e  f i r s t  t h r e e  h a s  a  D L T ,  a n  
additional three patients will be enrolled at that level.  If o nly one of six devel ops a DLT, then the 
dose will be escalated for the next three patients.  If two or more of the six have a DLT, then the 
dose will be de-escalated to the previous dose where an additio nal three patients will be treated.   
The MTD is defined as the highest dose at which 0 or 1 dose-lim iting toxicities are observed in 
six patients.  A total of 6 patient s will be treated at the MTD .  The target toxicit y with this type of 
design is less than 30%.    If there are two DLTs at the first dose level, a decreased dose  schedule of SGI-110, which is less 
myelosupressive, will be consider ed with a similar 3+3 escalati on of SGI-110.  The next dose level  
below dose level 1 (dose level -1) would consist of IRI 125 mg m
2 days 8 and 15 and SGI-110 30 
mg/m2 days 1-5. If no DLTs are encountered with dose level -1, the n ext three patients will be 
entered at dose level 1G, or IRI 125mg/m2 days 8, and 15 and SG I-110 45mg/m2 days 1-5. If one 
of the three patients has a DLT at dose level -1, an additional  three patients will be enrolled at that 
level. If only one of six develops a DLT, then the dose will be  escalated for the next three patients 
to dose level 1G. If two or more DLTs out of 6 are encountered at Dose level -1, at least an 
additional 3 patients will be enrolled at the lower dose level,  Dose level -1G. If 0/3 or 1/6 DLTs 
occur on Dose level -1G, the next  3 patients will be dose escal ated to Dose level  1G. If 2 or more 
DLTs out of 6 are experienced at Dose level -1G, the MTD will h ave been exceeded. 
 Figure 14.1.1. De-escalation Schema. 
 
 
1G
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
71  
Sample size/accrual rate for dose escalation:  The accrual rate for the dose escalation portion of 
this study is expected to be 3 patients per month.  The maximum  sample size in the dose escalation 
portion of the study could be 12 patients.  If no patients expe rience a DLT, 9 patients will be 
enrolled.   
 
Analysis of primary objective in dose escalation cohort: 
The number of dose-limiting toxi cities at each dose level will be reported.  Additional toxicity 
frequencies by type and grade wi ll be summarized by dose level for all doses.     
 
Analysis of secondary objectiv es in dose escalation: 
 
1) The design of this study will allow assessment of global and ca ndidate gene methylation 
differences at the tumor leve l.  We hypothesize that Irinotecan  resistance may be reversed 
with the use of the demethylating SGI-110 therapy.  Changes in global methylation by 
LINE-1 will be assessed in post-treatment biopsy specimens in t he dose escalation cohort 
for proof of the effect of SGI-110.  Changes will be plotted by  dose level and overall using 
boxplots of the log transformed raw data.  A paired t-test, or the nonparametric Wilcoxon 
signed rank test, will be used t o test if the changes are signi ficantly different from zero.  
Similar analyses will be used to assess gene expression changes  in WRN, DR1, TPAF2E, 
DEXI, BNIP3, and MED1.   
2) Pharmacokinetic (PK) sampling studies are proposed for all part icipating patients who 
undergo pharmacodynamic endpoints.  Single dose PK samples will  be collected on 
Cycle1, Day 1, at the following time points: pre-dose 0.25, 0.5 , 1, 1.5, 2, 3, 4, 6, and 8 hr.  
The following PK parameters describing the concentration time p rofile of SGI-110 will be 
calculated: total exposure will be calculated as area under the  plasma concentration-time 
curve (AUC) using the linear trapezoidal rule by using noncompa rtmental methods 
(Winonlin, version 5.3) and/or compartmental modeling (Adapt II , release 4.0).  Other 
parameters such as maximum concentration (C max), time to maximal concentration (T max) 
and half-life (T 1/2) will also be calculated. C max and T max will be obtained from the data, 
while the half-life will be calculated as 0.693/k, where k is t he slope of terminal elimination 
phase.  Associations between SGI-110 exposure parameters (C max and AUC) and 
pharmacodynamic endpoints (i.e., global methylation changes and  t o x i c i t y )  w i l l  b e  
assessed using appropriate non-parame tric statistical tests.   
 
Moving to Phase II Component : Our hypothesis is that SGI-110 treatment will sensitize colon  
cancer patients to retreatment with irinotecan.  Accordingly, i t will be important to see that the 
dose of SGI-110 that is at the MTD does have pharmacodynamics e ffects at the tumor level.  
Patient tumor biopsies post-treatment will be analyzed by LINE assay for demethylation to assess 
for at least 10% demethylation from baseline in the tumor biops ies.  We aim to see this level of 
demethylation in at least 60% of post-treatment biopsies as pre viously described in phase O 
studies. 
 
Phase II primary objective:  Evaluate the progression free s urvival (PFS) in patients receiv ing 
combination SGI-110 plus Irinotecan compared to standard of car e treatment with regorafenib or 
TAS-102.  Events are defined as disease progression or death fr om any cause. All patients treated 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
72 on protocol will be included in the determination of PFS, regar dless of treatment modification or 
discontinuation.   Epigenetic therapy may take several cycles to exert its maximal  benefit, and preclinical data has 
demonstrated initial tumor growth is possible prior to tumor sh rinkage. Patients on treatment with 
SGI-110 and IRI will be allowed to remain on study if their tum or progresses on RECIST 1.1 
criteria if they are 1) clinically stable, 2) their provider fe els it would be in thei r best interest, and 
3) the patient is informed of scan results and consents to rema in on treatment.  In this circumstance, 
they will be reimaged on schedule after 2 further cycles.  If t his subsequent imaging confirms 
progressive disease, the date of the progression even will be d ated to the first (initial) scan date 
that progression was first documented.   
Phase II secondary objectives: 
1. Evaluate and compare response rates between arms of the study a s determined by RECIST 
criteria 1.1. 
2. Evaluate and compare overall sur vival (OS) between arms of the study. 
3. Assess for potential predictive markers of survival using basel ine tissue. 
4. To assess the pharmacokinetics of SGI-110 in metastatic colon c ancer patients and 
correlate with changes in global methylation.  
 Sample Size/Accrual Rate: The median PFS of patients on the phase III CORRECT trial of 
Regorafenib in metastatic color ectal cancer reported by Grothey  and Van Cutsem was 1.9 
months.
11 The median PFS of patients on the phase III RECOURSE trial of TAS-102 in metastatic 
colorectal adenocarcinoma reported by Mayer15 was 2.0 months.  The PFS curves of these two 
trials were superimposable and therefore hazard rates over four  time intervals were estimated based 
on the published PFS curve (figure 3.) for Regorafenib from the  CORRECT trial.  Simple linear 
regressions were used to fit the natural logarithm of the Kapla n-Meier product limit estimate of 
the PFS function as a function of time in four intervals: from 1 to 6 weeks, 6 to 12, 12 to 18, and 
18 to 56 weeks.  These estimated hazard rates: 0.0113, 0.0558, 0.3238, and 0.0748 per person 
week were used in simulations to evaluate power for this study.   We hypothesize that the SGI-110 
combination treatment will improve the 4 month PFS from 23% to 46.5%.  Patients will be 
randomized to the SGI-110 + irinotecan (Arm A) and the Regorafe nib or TAS-102 arm (Arm B) 
in a 2:1 ratio.  Using a one sided 5% type I error allowance, a ccrual of 48 patients per year for 2 
years (Arm A and B target sample sizes of 64 and 32 respectivel y) with an additional 2 years of 
follow up, this study will provide sufficient events to have 83 % power to detect an improvement 
of the median PFS from 1.9 months to 3.6 months, i.e. a hazard ratio of 0.526. 
 Quality of Life Assessment : Quality of life will be assessed with the Functional Assessme nt of 
Cancer Therapy (FACT-C) quality of life tool.  An overall quali ty of life score for the domains: 
physical well-being, social/family well-being, emotional well-b eing, and functional well-being, as 
well as the colon cancer specific subscale score will be obtain ed at the start of the study (Cycle 1 
Day 1), at the beginning of cycle three (Cycle 3 Day 1), every other cycle subsequently (i.e. Cycle 
5 Day 1, Cycle 7 Day 1, etc), and at the off study visit for ev ery patient.  Scoring will follow 
guidelines provided by FACIT administration guidelines manual.   The change in total score 
between pre-treatment and the st art of cycle three will be comp ared between arms of the study 
with a t-test.  Two subscale sums of the total score: the sum o f physical and functional well-being, 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
73 and the sum of social/family and emotional well-being, will be similarly analyzed.  The change in 
the colon cancer specific domain will also be compared between arms of the study.  We anticipate 
that we will have minimal missing data at the start of cycle 3 as this is the first time a patient could 
come off study for progression.  A t this time point, any missin g data would be due to DLTs, SAE 
events, or voluntary withdrawal.  In these cases, documentation  of the reason for missing data and 
the QoL at the time of withdraw al will be obtained with the off  study evaluation. 
 
Futility monitoring plan:  We will monitor the study for futility using a non-parametric B ayesian 
predictive probability approach.40-42 This monitoring plan is based on calculations of the posterior  
distribution of the survival di stribution and simulations to de termine the probability that the PFS 
at 4 months on the treatment arm will be greater than that on t he control arm at the end of the 
study.  When the trial is monitored, Gibbs sampling is used to generate samples from the posterior 
distribution of the sur vival distribution vi a Monte Carlo simul ation, given the data and a Dirichlet 
process prior.  Censored observa tions are treated as random qua ntities and PFS event times are 
simulated for each censored obs ervation.  This is repeated many  times and ultimately converges 
to a realization of the parameters drawn from the posterior dis tribution.  The algorithm is that 
reported in Kuo and Smith.42  If the probability that the treatment 4 month PFS is greater than the 
control PFS at 4 months is very l ow, less than 33.3%, the study  will be stopped for futility.   
 
The reference hazard rates we re estimated based on the publishe d PFS curve (figure 3.) for 
Regorafenib.11  Simple linear regressions wer e used to fit the natural logari thm of the Kaplan-
Meier product limit estimate of t he survival function as a func tion of time in four intervals: from 
1 to 6 weeks, 6 to 12, 12 to 18, and 18 to 56 weeks.  Survival times were then generated using a 
piecewise exponential distributi on with these estimated hazard rates: 0.0113, 0.0558, 0.3238, and 
0.0748 per person week.  For simulation purposes, the effect of  treatment was assumed to 
multiply these hazard rates by factors of 1.0 (no difference), 0.80, 0.60, 0.526, 0.50, 0.40 and 
0.35.  The randomization ratio for t hese simulated studies was 2:1 and a single interim analysis, 
evaluating 4 month PFS, was perf ormed after 50% of the patients  were enrolled, i.e. n=32 in 
Arm A (SGI-110) and n=16 in Arm B  (Regorafenib or TAS-102).  A one-sided 0.05 alpha level 
log-rank test was used for the f inal analysis.  Plots of the re ference curve (black) and six 
scenarios of treatment effects (red) are shown in figure 1.  In  scenario one, the reference and 
treatment hazard rates are equa l.  Table 1 gives operating char acteristics of this monitoring plan 
for these scenarios.  Colum n 4 in table 1 is the proportion of studies rejecting the null hypothesis 
out of the number of studies tha t did not stop for futility.  C olumn 5 is the overall proportion of 
studies with a positive result.   Table 1.  Operating characteristic s of monitoring rule from 500  simulated studies with interim 
analysis on 4 month PFS and final  analysis based on the log-ran k test. 
  
Scenario Control 
hazard 
rate (λ) 
multiplier Stop for 
Futility % Rejected at 
final 
analysis %* Overall 
studies rejecting Ho 
% 
1 1.00 26.4% 5.4% 4.0% 
2 0.80 12.8% 22.0% 19.2% 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
74 3 0.60 5.2% 68.8% 65.2% 
4 0.526 2.0% 84.7% 83.0% 
5 0.50 1.2% 89.1% 88.0% 
6 0.40 0.6% 98.4% 97.8% 
7 0.35 0.0% 99.8% 99.8% 
 *Denominator is the number of  simulations that do not stop ear ly for futility. 
 
 
Analysis of primary objective: 
Standard life table methods will be used to analyze PFS.  We wi ll report the 4-month, 1-year and 
median PFS with 95% confidence in tervals for both arms of the s tudy.   
 
Analysis of secondary objectives: 
 
1. The 4-month PFS will be compared between arms of the study usin g a one-sided, 0.05 
alpha level, log-rank test.  
2. All patients included in the  study must be assessed for respons e to treatment, even if there 
are major protocol treatment deviations. Each patient will be a ssigned one of the following 
categories: 1) complete response, 2) partial response, 3) stabl e disease, 4) progressive 
disease, 5) early death from ma lignant disease, 6) early death from toxicity, 7) early death 
because of other cause, or 9) unknow n (not assessable, insuffic ient data).  
All subjects in the study will be included in the main analysis  of the response rate. Patients 
in response categories 4-9 should be considered to have a treat m e n t  f a i l u r e  ( d i s e a s e  
progression). Thus, an incorrect t reatment schedule or drug adm inistration does not result 
in exclusion from the analysis of the response rate.  Response rate will be estimated overall 
and by treatment arm.  A Fisher’s  Exact or chi square test will  be use to compare response 
rates across treatment arms.   
3. Standard life table methods will be used to analyze OS.  Four m onth, 1-year and median 
survival will be reported, overall and by treatment arm. We ack nowledge that OS 
assessment will be compromise d with the cross-over design and w ill report as such. 
4. Baseline global methylation will be categorized as high or low and OS Kaplan Meier 
curves plotted by category.  The change in global methylation w ill be categorized as 
positive or negative and OS Kaplan Meier curves plotted by cate gory.  Similar analyses 
will be used for individu al expression markers. 
5. Pharmacokinetic (PK) sampling studies are proposed for all part icipating patients who 
undergo pharmacodynamic endpoints.  Single dose PK samples will  be collected on 
Cycle1, Day 1, at the following time points: pre-dose 0.25, 0.5 , 1, 1.5, 2, 3, 4, 6, and 8 hr.  
The following PK parameters describing the concentration time p rofile of SGI-110 and 
Irinotecan will be calculated: total exposure will be calculate d as area under the plasma 
concentration-time curve (AUC) using the linear trapezoidal rul e by using 
noncompartmental methods (Winonlin, version 5.3) and/or compart mental modeling 
(Adapt II, release 4.0).  Other parameters such as maximum conc entration (C max), time to 
maximal concentration (T max) and half-life (T 1/2) will also be calculated. C max and T max will 
be obtained from the data, while  the half-life will be calculat ed as 0.693/k, where k is the 
slope of terminal elimination phase.  Associations between SGI- 110 exposure parameters 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
75 (Cmax and AUC) and pharmacodynamic endpoints (i.e., global methylati on changes toxicity 
and toxicity) will be assessed us ing appropriate non-parametric  statistical tests.   
Stratification Factors 
 Patients will be stratified by two factors: assignment to Regor afenib or TAS-102, and time 
from last irinotecan treatment (>6 months or < 6 months) throug h an algorithm to maintain 
balance between the arms as much as possible. 
14.2 Reporting and Exclusions 
 
14.2.1  Evaluation of toxicity. All participants will be evaluable for toxicity 
from the time of their first treatment. 
14.2.2  Evaluation of response.   All participants included in the study must be 
assessed for response to treatment.  Each participant should be  assigned 
one of the following categories:  1) complete response, 2) parti al 
response, 3) stable disease, 4) progressive disease, 5) early d eath from 
malignant disease, 6) early death from toxicity, 7) early death  because of 
other cause, or 9) unknown (not ass essable, insufficient data).  By 
arbitrary convention, category 9 usually designates the "unknow n" status 
of any type of data in a clinical database. 
  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
76  
15 REFERENCES  
 
1. Investigator Brochure SGI-110. 
2.  Yoo, C.B., Jeong, S., Egger, G., et al., Delivery of 5-Aza- 2'-Deoxycytidine to Cells Using 
Oligodeoxynucleotides . Cancer Res, 2007. 67(13):6400-6408. 
3. Chuang, J.C., Warner, S.L., Vollmer, D., et al., S110, a 5-A za-2'-Deoxycytidine-Containing 
Dinucleotide, Is an Effective DNA Methylation Inhibitor In vivo  and Can Reduce Tumor 
Growth . Molecular Cancer Therapeutics, 2010. 9(5):1443-1450. 
4.  Dacogen, Dacogen (decitabine f or injection) P rescribing Inf ormation. 2010. 
5.  Issa, J.P., Roboz, G., Rizzieri, D., et al. Interim Results  from a randomized Phase 1-2 first-
in-human (FIH) study of PK/PD guided escalating doses of SGI-11 0, a novel subcutaneous (SQ) 
second generation hypomethylating agent (HMA) in relapsed/refra ctory MDS and AML. in In: 
Proceedings of the 103rd Annual Meeting of the American Associa tion for Cancer Research; 
2012 Mar 31-Apr 4; Chicago, IL Abstract Number LB-214. 2012. 
6.  Fuchs C, Mitchell EP, Hoff PM. Irinotecan in the treatment of colorectal cancer. Cancer 
Treat Rev. 2006 Nov;32(7):491-503. 
7.  Camptomsar (irinotecan for i njection) Prescribing Informati on. 2012. 
8. Chu E. An update on the current  and emerging targeted agents  in metastatic colorectal 
cancer. Clin Colorect al Cancer, 11 (2012), pp. 1–13. 
 9.  SM Wilhelm, J Dumas, L Adnane et al. Regorafenib (BAY 73-4506): a new oral 
multikinase inhibitor of angiogenic, stromal and oncogenic rece ptor tyrosine kinases with 
potent preclinical antitumor  activity  Int J Cancer, 129 (2011) , pp. 245–255. 
 10.   D Strumberg, ME Scheulen, B Schultheis et al. Regorafenib (BAY 73-4506) in 
advanced colorectal cancer:  a phase I study.  Br J Cancer, 106 (2012), pp. 1722–1727. 
 11.   Grothey A, Van Cutsem E, S obrero A, Siena S, Falcone A, Y chou M, Humblet Y, 
Bouch O, Mineur L, Barone C, Ade nis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, 
Sargent DJ, Cihon F, Cupit L, Wagne r A, Laurent D; CORRECT Stud y Group. Regorafenib 
monotherapy for previously treat ed metastatic colorectal cancer  (CORRECT): an international, 
multicentre, randomised, placebo-controlled, phase 3 trial. Lan cet. 2013 Jan 26;381(9863):303- 
 12.   FDA approves regorafenib (Stiv arga) for metastatic colore ctal cancer. Oncology 
(Williston Park). 2012 Oct;26(10):896.  
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
77 13. Tanaka N, Sakamoto K, Okabe H , Fujioka A, Yamamura K, Nakag awa F, Yokogawa 
T, Oguchi K, Ishida K, Osada A, Kazuno H, Yamada Y, Matsuo K. R epeated oral dosing of 
TAS-102 confers high trifluridine incorporation into DNA and su stained antitumor activity in 
mouse models. Oncol R ep. 2014 Dec; 32(6):2319-26. 
 14. Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Ba ba H, Tsuji A, 
Yamaguchi K, Muro K, Sugimoto N, Ts uji Y, Moriwaki T, Esaki T, Hamada C, Tanase T, 
Ohstsu A. TAS-102 monotherapy for  pretreated metastatic colorec tal cancer: a double-blind, 
randomized, placebo-controlled pha se 2 trial. Lancet Oncol. 201 2 Oct; 13(10):993-1001. 
 15. Mayer RJ, Van Cutsem E, Fal cone A, Yoshino T, Garcia-Carbon ero R, Mizunuma 
N, Yamazaki K, Shimada Y, Taber nero J, Komatsu Y, Sobrero A,Bou cher E, Peeters M, Tran 
B, Lenz HJ, Zaniboni A, Hochster  H, Cleary JM, Prenen H, Benede tti F, Mizuguchi H, Makris 
L, Ito M, Ohtsu A; RECOURSE S tudy Group.  Randomized trial of T AS-102 for refractory 
metastatic colorectal cancer .  N Engl J Med. 2015 May 14;372(20 ):1909-19. 
 
16. “Trifluridine/tipiracil.” FDA . Retrieved from 
http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm46 3743.htm 
 17.   Siegel R, DeSantis C, Virgo K , Stein K, Mariotto A, Smith  T, Cooper D, Gansler T, 
Lerro C, Fedewa S, Lin C, Leac h C, Cannady RS, Cho H, Scoppa S,  Hachey M, Kirch R, 
Jemal A, Ward E. Cancer treatme nt and survivorship statistics, 2012. CA  Cancer J Clin. 2012 
Jul-Aug;62(4):220-41.  18.   Geh JI, Ma YT. Evolution of s ystemic therapy for metastat ic colorectal cancer. 
Colorectal Dis. 2011 Aug;13(8):852-4. 
 19.   Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, C oleman B, Sebree R, 
Rodgers K, Hooker CM, Franco N, L ee B, Tsai S, Delgado IE, Rude k MA, Belinsky SA, 
Herman JG, Baylin SB, Brock MV , Rudin CM. Combination epigeneti c therapy has efficacy in 
patients with refractory advan ced non-small ce ll lung cancer. C ancer Discov. 2011 
Dec;1(7):598-607.  20.   Ishiguro M, Iida S, Uetake H, Morita S, Makino H, Kato K,  Takagi Y, Enomoto 
M,Sugihara K. Effect of combine d therapy with low-dose 5-aza-2' -deoxycytidine and 
irinotecan on colon cancer cell line HCT-15. Ann Surg Oncol. 20 07 May;14(5):1752-62. 
 21.   Tanaka T, Bai T, Toujima S, Utsunomiya T, Matsuoka T, Kob ayashi A, Yamamoto 
M,Sasaki N, Tanizaki Y, Utsunomiy a H, Tanaka J, Yukawa K. Demet hylation restores SN38 
sensitivity in cells with acquire d resistance to SN38 derived f rom human cervical squamous 
cancer cells. Oncol Rep. 2012 Apr;27(4):1292-8.  22.   Crea F, Giovannetti E, Cor tesi F, Mey V, Nannizzi S, Gall egos Ruiz MI, 
Ricciardi S, Del Tacca M, Peters GJ, Danesi R. Epigenetic mecha nisms of 
irinotecan sensitivity in colorectal cancer cell lines. Mol Can cer Ther. 2009 
Jul;8(7):1964-73. 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
78  
23.   LoRusso PM, Boerner SA, S eymour L. An overview of the opt imal planning, 
design, and conduct of phase I st udies of new therapeutics. Cli n Cancer Res. 2010 Mar 
15;16(6):1710-8.  24.   Mandrekar SJ, Sargent DJ . Randomized phase II trials: tim e for a new era in 
Clinical trial design. J Thor ac Oncol. 2010 Jul;5(7):932-4. 
 25.   Silverman, L. R., Fenaux, P., Mufti, G. J., Santini, V., Hellström-Lindberg, E., 
Gattermann, N., Sanz, G., List, A. F., Gore, S. D. and Seymour,  J. F. (2011), Continued 
azacitidine therapy beyond time of first response improves qual ity of response in patients with 
higher-risk myelodysplas tic syndromes. Cancer, 117: 2697–2702. 
 26.   Yodaiken, R.E. and Bennett, D., OSHA work-practice guidel ines for personnel dealing 
with cytotoxic (antineoplastic)  drugs. Occupational Safety and Health Administration . Am J 
Hosp Pharm, 1986. 43(5):1193-204.  27.   Stivarga (regorafenib) Prescribing Information. 2012. 
 28.   National Cancer Institute , Common Terminology Criteria fo r Adverse Events v4.0 NCI, 
NIH, DHHS. May 29, 2009, N IH publication # 09-7473. 
 29.   Smith, T.J., Khatcheressian, J., Lyman, G.H., et al., 200 6 update of recommendations 
for the use of white blood cell growth factors: an evidence-bas ed clinical practice guideline . J 
Clin Oncol, 2006. 24(19):3187-205. 
 
30.   Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Me thylation specific PCR: 
A novel PCR assay for methylation status of CpG islands. Proc N atl Acad Sci U S A 1996 Sep 
3;93(18):9821-6.   31.   Herman, J. G. et al. Incidence and functional consequence s of hMLH1 promoter 
hypermethylation in colorectal car cinoma. Proc. Natl. Acad. Sci . U. S. A. 95, 6870-6875 
(1998).  32.   Suzuki, H. et al. Epigenetic i nactivation of SFRP genes a llows constitutive WNT 
signaling in colorectal can cer. Nat. Genet. 36, 417-422 (2004).  
 33.   Toyota, M. et al. CpG isla nd methylator phenotype in colo rectal cancer. Proc. Natl. 
Acad. Sci. U. S. A. 96, 8681-8686 (1999).  34.   Herman JG. Circulating methylated DNA. Ann N Y Acad Sci 2 004 Jun;1022:33-9.  
 35.   Bailey VJ, Zhang Y, Keeley B P, Yin C, Pelosky KL, Brock M , Baylin SB, Herman JG, 
Wang TH. Single-tube analysis  of DNA methylation with silica 
superparamagnetic beads. C lin Chem. 2010 Jun;56(6):1022-5. 
 
J1369, SGI-110 + irinotecan vs. regorafenib or TAS 102  Version 2.0 February 5, 2020    
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
79 36.   Nakayama G, Hibi K, Kodera Y , Koike M, Fujiwara M, Nakao A. P16 methylation in 
serum as a potential marker for the malignancy of colorectal ca rcinoma. Anticancer Res. 2007; 
27(5A):3367-70.   37.   Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K,  Akiyama S, Nakao A. 
Molecular detection of p16 promoter  methylation in the serum of  recurrent colorectal cancer 
patients. Int J Cancer. 2003;105(4):491-3.   38.   Leung WK, To KF, Man EP, Cha n MW, Bai AH, Hui AJ, Chan FK , Sung JJ.  
Quantitative detection of promot er hypermethylation in multiple  genes in the serum of  
patients with colorectal cancer . Am J Gastroenterol. 2005;100(1 0):2274-9.  
 39.   Eisenhauer EA, Therasse P, B ogaerts J, Schwartz LH, Sarge nt D, Ford R, Dancey J, 
Arbuck S, Gwyther S, Mooney M, Rubi nstein L, Shankar L, Dodd L,  Kaplan R, Lacombe D, 
Verweij J. New response evaluati on criteria in solid tumours: r evised RECIST guideline 
(version 1.1). Eur J Cancer 45(2): 228 - 47, 2009.   40. Susarla, V. and Ryzin, J.V. Nonparametric Bayesian estimati on of survival curves from 
incomplete observations.  Journal  of the American Statistical A ssociation 1976;71:879-902.
 
 
41. Kuo, L. and Smith, A.F.M. (1992).  Bayesian computations in  survival models via the Gibbs 
sampler.  In Survival Analysis: S tate of the Art, J.P. Klein an d P.K. Goel (eds), 11-24. Dordrecht, 
the Netherlands: Kluwer Academic Publishers.  
 
42. Rosner, G.L.  Bayesian monitoring of clinical trials with f ailure-time endpoints.  Biometrics 
2005; 61:239-245. 
  
 
 
Version 1.3, April 21, 2014 
 
CONFIDENTIAL 
This document is confidential. D o not disclose or use except as  authorized. 
 
80 Appendix A: Performan ce Status Criteria 
 
 
ECOG Performance Status Scale 
  
Karnofsky Performance Scale 
Grade Description Percent Description 
0 Normal activity. Fully active, able 
to carry on all pre-disease performance without restriction. 100 Normal, no complaints, no 
evidence of disease. 
90 Able to carry on normal activity; 
minor signs or symptoms of disease. 
1 Symptoms, but ambulatory. 
Restricted in phys ically strenuous 
activity, but ambulatory and able to carry out work of a light or sedentary nature (e.g., light housework, office work). 80 Normal activity with effort; 
some signs or symptoms of disease. 
70 Cares for self, unable to carry on 
normal activity or to do active work. 
2 In bed < 50% of the time. 
Ambulatory and capable of all self-care, but unable to carry out any work activities. U p and about more 
than 50% of waking hours. 60 Requires occasional assistance, 
but is able to care for most of his/her needs. 
50 Requires considerable assistance 
and frequent medical care. 
3 In bed >50% of the time. Capable 
of only limited self-care, confined to bed or chair more than 50% of waking hours. 40 Disabled, requires special care 
and assistance. 
30 Severely disabled, 
hospitalization indicated. Death not imminent. 
4 100% bedridden . Completely 
disabled. Cannot carry on any self-care. Totally confined to bed or chair. 20 Very sick, hos pitalization 
indicated. Death not imminent. 
10 Moribund, fatal processes 
progressing rapidly.  
5 Dead. 0 Dead. 
 
  
 
   
81APPENDIX B:   PATIENT DIARY  
Today’s date:  _________________________ 
Agent:   Regorafenib _____ mg daily  
Patient instructions: Regorafe nib should be taken with a low-fa t meal once a day. 
 
  ____________________  Patient Signature   ____________________  Date  Study 
Day Date Time of 
Dose # Tablets 
taken Blood Pressure
(Cycle 1, Days 
1, 8, 15, and 22 
& Cycle 2, Days 
1 and 8) Comments
 
1      
2      
3      
4      
5      
6      
7      
8      
9      
10      
11      
12      
13      
14      
15      
16      
17      
18      
19      
20      
21      
22      
23      
24      
25      
26      
27      
28      
 
   
82APPENDIX C:   PATIENT DIARY 
Today’s date  _________________________ 
Agent :  TAS-102 ________ mg twice daily  
Patient instructions: TAS-102 s hould be taken twice daily withi n one hour after a meal. 
 
   ____________________  Patient Signature   ____________________  Date 
  Study 
Day Date Time of 
AM Dose Time of 
PM Dose # Tablets 
taken 
AM / PMComments
 
1    /  
2    /  
3    /  
4    /  
5    /  
6      
7      
8    /  
9    /  
10    /  
11    /  
12    /  
13      
14      
15      
16      
17      
18      
19      
20      
21      
22      
23      
24      
25      
26      
27      
28      
 
   
83APPENDIX D: FACT-C (Version 4) 
 
Study #: ________________________ Subject ID: _________________ ________ 
 Subject initials: __________________  Subject date of birth: __ _______________ 
 Today’s date: ____________________  
Below is a list of statements th at other people with your illne ss have said are important . 
Please circle or mark one number per line to indicate your resp onse as it applies to 
the past 7 days.  
 
 PHYSICAL WELL-BEING 
 Not 
at all A little 
bit Some-
what Quite
a bit Very 
much 
GP1 I have a lack of 
energy .............................................................. ............................ 0 1 2 3 4 
GP2 I have 
nausea .............................................................. ............................ 0 1 2 3 4 
GP3 Because of my physical condition, I have trouble 
meeting the needs of my family .............................................................. ............................  
0  
1  
2  
3  
4 
GP4 I have pain .............................................................. ............................ 0 1 2 3 4 
GP5 I am bothered by side effects of 
treatment .............................................................. ............................ 0 1 2 3 4 
GP6 I feel 
ill .............................................................. ............................ 0 1 2 3 4 
GP7 I am forced to spend time in 
bed .............................................................. ............................0 1 2 3 4 
 
 SOCIAL/FAMILY WELL-BEING 
 Not 
at all A little 
bit Some-
what Quite
a bit Very 
much 
 
   
84 
Please circle or mark one numb er per line to indicate your resp onse as it applies to 
the past 7 days. 
 
 EMOTIONAL WELL-BEING Not 
at all A little 
bit Some-
what Quite
a bit Very 
much 
GE1 I feel 
sad .............................................................. ............................ 0 1 2 3 4 GS1 I feel close to my 
friends .............................................................. ............................ 0 1 2 3 4 
GS2 I get emotional support from my 
family .............................................................. ............................ 0 1 2 3 4 
GS3 I get support from my 
friends
 .............................................................. ............................ 0 1 2 3 4 
GS4 My family has accepted my 
illness .............................................................. ............................ 0 1 2 3 4 
GS5 I am satisfied with famil y communication about my 
illness .............................................................. ............................  
0  
1  
2  
3  
4 
GS6 I feel close to my partner (or the person who is my main 
support) .............................................................. ............................  
0  
1  
2  
3  
4 
Q1 Regardless of your current level of sexual activity, please 
answer the following question. If you prefer not to answer it, please mark this box           and go to the next section.       
GS7 I am satisfied with my sex 
life .............................................................. ............................ 0 1 2 3 4 
 
   
85GE2 I am satisfied with how I am coping with my 
illness .............................................................. ............................ 0 1 2 3 4 
GE3 I am losing hope in the fight against my 
illness .............................................................. ............................ 0 1 2 3 4 
GE4 I feel 
nervous .............................................................. ............................ 0 1 2 3 4 
GE5 I worry about 
dying .............................................................. ............................ 0 1 2 3 4 
GE6 I worry that my condition will get 
worse .............................................................. ............................ 0 1 2 3 4 
 
 
 FUNCTIONAL WELL-BEING 
 Not 
at all A little 
bit Some-
what Quite
a bit Very 
much 
 
GF1 I am able to work (include work at 
home) .............................................................. ............................ 0 1 2 3 4 
GF2 My work (include work at home) is 
fulfilling .............................................................. ............................ 0 1 2 3 4 
GF3 I am able to enjoy 
life .............................................................. ............................ 0 1 2 3 4 
GF4 I have accepted my 
illness .............................................................. ............................ 0 1 2 3 4 
GF5 I am sleeping 
well .............................................................. ............................ 0 1 2 3 4 
 
   
86GF6 I am enjoying the things I usually do for 
fun .............................................................. ............................ 0 1 2 3 4 
GF7 I am content with the quality of my life right 
now .............................................................. ............................ 0 1 2 3 4 
Please circle or mark one numb er per line to indicate your resp onse as it applies to 
the past 7 days. 
 
 
 ADDITIONAL CONCERNS 
 Not 
at all A little 
bit Some-
what Quite 
a bit Very 
much 
C1 I have swelling or cramps in my stomach 
area .............................................................. ............................ 0 1 2 3 4 
C2 I am losing 
weight .............................................................. ............................ 0 1 2 3 4 
C3 I have control of my 
bowels .............................................................. ............................ 0 1 2 3 4 
C4 I can digest my food 
well .............................................................. ............................ 0 1 2 3 4 
C5 I have diarrhea 
(diarrhoea) .............................................................. ............................ 0 1 2 3 4 
C6 I have a good 
appetite .............................................................. ............................ 0 1 2 3 4 
C7 I like the appearance of my 
body .............................................................. ............................ 0 1 2 3 4 
Q2 Do you have an ostomy appliance?  (Mark one box)         No or         Yes 
 If yes, please answer t he next two items:  
 
   
87C8 I am embarrassed by my ostomy 
appliance .............................................................. ............................ 0 1 2 3 4 
C9 Caring for my ostomy appliance is 
difficult .............................................................. ............................ 0 1 2 3 4 
 
  